Search this site

Key Points from The Future of HealthTech 2025 report by Silicon Valley Bank Exec Summary The single most significant key point from the Silicon Valley Bank (SVB) Future of HealthTech 2025 report is the dramatic shift of venture capital investment towards AI-enabled Provider Operations. Here's a breakdown of the central finding: Provider Operations Overtakes Alternative Care: Investment in Provider Operations (administrative and back-office functions like scheduling, documentation and billing, which is essential to the delivery of healthcare) now accounts for a massive 44% of total HealthTech funding, surpassing the previous investment leader, alternative care. The AI Driver: This surge is driven by the adoption of AI-enabled solutions aimed at solving business problems and improving efficiency. The report states that 52% of 2025 provider-operations deals involve AI. Record-Setting Investment: This sub-sector is on track to have its biggest investment year ever, projected to break its 2021 record. The Future of HealthTech 2025 Report The Future of HealthTech 2025 Report by Silicon Valley Bank (SVB) highlights a significant shift in venture capital (VC) investment, with a strong focus on AI-enabled provider operations. Key takeaways from the report include: Provider Operations Dominates Funding: Investment is shifting dramatically, with provider operations (activities like scheduling, documentation and billing) capturing 44% of HealthTech funding. This sub-sector is on track for its biggest investment year ever, projected to surpass its 2021 record. The AI Boom: AI-driven solutions are the main catalyst for this shift, transforming administrative and clinical workflows. 52% of 2025 provider-operations deals involve AI, and seed-stage AI valuations have seen a boost of around 42% since 2021. Decline in Alternative Care: Conversely, the share of investment going to alternative care has fallen sharply, from 42% in 2021 to just 9% today. M&A is the Primary Exit Strategy: As initial public offerings (IPOs) remain challenging, consolidation through mergers and acquisitions (M&A) has become the dominant exit strategy, particularly within provider operations. Concentration Risk: The report notes a concentration of capital, with mega-deals (those relying on valuation premiums, often from generalist investors) making up 38% of total Healthtech investment. A significant portion of the total invested in 2025 went to a single company. The report suggests that the HealthTech sector is becoming more focused on solving business and operational inefficiencies using AI, rather than exclusively focusing on clinical care problems. Source: https://www.svb.com/globalassets/trendsandinsights/reports/healthcare/2025/future-of-healthtech-2025-v2.pdf Key Predictions The Silicon Valley Bank (SVB) Future of HealthTech 2025 Report outlines several key predictions and ongoing trends that will shape the sector through the end of the year and beyond: 1. Dominance of AI-Enabled Provider Operations Investment Shift: The core prediction is that AI-enabled provider operations will continue to drive the sector, capturing the majority of venture capital. This sub-sector, which focuses on administrative efficiency (scheduling, documentation, billing), is on pace for its biggest investment year ever, projected to reach $8.25 Billion and account for 44% of total HealthTech investment. The Focus is Business: HealthTech is predicted to be, in the near term, an administrative sector, not a clinical one, as companies prioritise using AI to solve fundamental business and workflow inefficiencies for stronger ROI. 2. M&A as the Primary Exit Strategy Consolidation: With IPOs remaining scarce, mergers and acquisitions (M&A) will continue to be the most realistic and dominant path for exits. Consolidation, often via strategic investors and private equity "roll-ups" in the provider operations space, is expected to continue at a high pace. PE Activity: The report anticipates a record number of HealthTech private equity (PE) exits by year-end. 3. Rising Valuations and Concentration Risk AI Valuation Inflation: Median valuations for early-stage AI companies are predicted to continue climbing, potentially creating an "AI bubble." Seed-stage AI valuations have already risen approximately 42% since 2021. Concentration: Investment is predicted to remain highly concentrated in fewer, larger rounds (mega-deals), which often rely on a valuation premium provided by generalist investors. This signals a concentration risk where a large percentage of total funding is committed to a small number of top-performing companies. Silicon Valley Bank (SVB) and HealthTech SVB's relationship with the HealthTech sector is historically deep, driven by: Commercial Banking and Lending: SVB traditionally provided crucial commercial banking services, loans, and other capital to early-stage, high-growth technology and life science companies, which often struggle to get financing from traditional banks. Market Insights: The bank's reports (like the one you inquired about) are an essential source of data for investors and founders, providing deep sector-specific analysis that informs investment strategies. The Post-Collapse Context: Following the bank's collapse in early 2023, its assets and operations were acquired by First Citizens Bank. The new entity retains the commitment to serving the innovation economy, including HealthTech, leveraging the deep sector expertise of the former SVB teams. HealthTech in the US The US market is the largest and most dominant in global HealthTech investment, characterised by: Massive Investment Scale: The US has historically received the lion's share of global HealthTech VC funding, offering a massive potential customer base and significant revenue opportunities. AI and Provider Operations Focus: As highlighted in SVB's 2025 report, the US market is currently prioritising investments in AI-enabled provider operations. The focus is on solving administrative inefficiencies for clear, near-term ROI. Receptivity to Innovation: The market is generally receptive to new technologies, but the healthcare system is highly fragmented across numerous payers and providers, creating a complex regulatory and market-entry landscape. High-Stakes Environment: While offering higher reimbursement rates than many other markets, the US has intense competition and the stakes for success (and failure) are very high. HealthTech in Europe The European market is known for its rapid growth and fragmentation, which presents both unique opportunities and challenges: Fastest-Growing Region (Historically): Europe, and particularly the UK, has been one of the fastest-growing regions for HealthTech investment, although it started from a lower base than the US. UK Leadership: The United Kingdom (especially the "Golden Triangle" of London, Oxford, and Cambridge) is typically the leading hub for HealthTech investment in Europe, known for its strong research base and proximity to the NHS. Market Fragmentation: A major challenge is the fragmentation of healthcare systems across different countries (France, Germany, Nordic regions, etc.). Each country maintains control over its own national system, leading to variations in procurement, reimbursement, and regulatory approval, which complicates scaling across the continent. Focus Areas: European companies are also innovating across various areas, including digital therapeutics, chronic care management, and physician support tools, often driven by different policy and public health priorities compared to the US. Regulatory Challenges: Navigating varied national reimbursement policies, language barriers, and the complexities of regulations like the EU's Medical Device Regulation (MDR) remain significant hurdles for European startups trying to scale Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

10 Key Factors European HealthTech Founders should be aware of in today's M&A and funding environment The European HealthTech M&A and funding environment is characterised by a "flight to quality," increased investor selectivity, and a strong focus on proven business models and clear pathways to profitability. The market is maturing, favouring larger, strategic deals and companies with demonstrable clinical and financial success. Here are 10 key factors European HealthTech founders should be aware of: 1. Focus on Profitability and Recurring Revenue Investors and acquirers have shifted from prioritising growth at all costs to demanding a clear path to profitability and strong unit economics. Valuation Premium: Companies with a high percentage of recurring revenue (e.g., Software-as-a-Service/subscription models) and high gross margins are receiving premium valuations (often 5.5x to 7x revenue multiples for value-based care/analytics solutions). Founder Focus: Clean up your financials and demonstrate a predictable, scalable revenue model that isn't dependent on one-off projects. 2. Definitive Clinical and Commercial Validation Unlike general tech, HealthTech's value is directly tied to real-world efficacy and measurable impact. Evidence is King: Buyers require robust, documented clinical studies and clear Return on Investment (ROI)for providers and payers. Due Diligence: Expect intense scrutiny on documented case studies that prove your product improves patient outcomes or generates cost savings. 3. Regulatory Compliance and Data Privacy (GDPR/EHDS) Regulatory risk is a major deal-breaker in due diligence, especially in Europe's complex, fragmented regulatory landscape. GDPR & Security: Meticulous documentation and a flawless track record of adherence to GDPR (data privacy) and a formal Quality Management System (QMS) are non-negotiable. EHDS Impact: The impending European Health Data Space (EHDS) aims to create a single market for health data, offering immense opportunity but requiring strict adherence to new data sharing and interoperability standards. Compliance here is a new value driver. 4. Proprietary AI and Deep Technology "Moat" AI/ML is the single biggest driver of valuation premiums, but only for proven, defensible technology. Premium Valuation: Companies with proprietary AI/ML algorithms that provide a clear competitive advantage (e.g., in diagnostics or predictive analytics) are seeing top-tier valuations (often 6x to 8x revenue multiples or more). Founder Focus: Clearly document and protect your unique technology Intellectual Property (IP) and be ready to demonstrate measurable outcomes and efficiency gains it provides. 5. Shift to Selective Scale and Late-Stage Investment The funding environment is heavily concentrated, with investors favouring larger, more mature companies. "Mega-Deals" Dominance: A few large late-stage deals ($100M+) are capturing a significant share of the total VC funding, indicating a "flight to quality". Early-Stage Caution: Early-stage companies face greater scrutiny, requiring stronger traction, a solid team, and clear evidence of product-market fit to secure initial funding. 6. Fragmented European Market and Cross-Border Scaling Scaling across Europe remains a core challenge due to national differences in healthcare systems. Market Fragmentation: Each member state has its own unique reimbursement, procurement, and adoption processes, making pan-European scaling costly and complex. Opportunity: Companies that successfully build solutions for interoperability, compliance SaaS, or systems integration that bridge this fragmentation are high-value M&A targets. 7. Importance of a Strong, Scalable Management Team Acquirers are risk-averse regarding over-reliance on a single founder. Key Person Risk: Due diligence assesses if the company can operate and grow without the founder's daily involvement. A lack of a strong second-tier management team is a red flag. Founder Focus: Develop documented, repeatable processes (SOPs) and delegate key client relationships to demonstrate sustainability and scalability post-acquisition. 8. M&A as the Primary Exit Path With the IPO market remaining largely stagnant, M&A is the dominant route to liquidity. Acquirer Profile: Expect increased interest from large US and Asian strategic buyers seeking platform opportunities and access to the European market, alongside large European biopharma/MedTech players filling portfolio gaps. Alternative Structures: Be prepared for a rise in alternative deal structures like earn-outs and milestone-driven payments, which manage risk for acquirers in volatile markets. 9. Alignment with Value-Based Care and Cost Reduction The rising cost of healthcare puts pressure on providers to adopt solutions that deliver measurable savings. Investor Preference: Solutions that clearly enable the shift from a fee-for-service to a value-based care model are attracting high multiples. Founder Focus: Your pitch should centre on verifiable cost savings and clinical efficiency gains for healthcare systems, not just novel technology. 10. Geopolitical and Macroeconomic Headwinds Rising interest rates and global economic uncertainty continue to impact valuations and deal financing. Valuation Compression: While resilient, the average revenue multiple is down from its 2021 peak, leading to valuation compression for smaller or less profitable startups. Capital Costs: Higher interest rates make it more expensive for buyers to finance large transactions, contributing to the cautious nature of the M&A market. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

HealthTech and MedTech IPO predictions 2026 HealthTech and MedTech IPO Predictions 2026: The Discipline Shift and AI-Driven Resurgence The Initial Public Offering (IPO) landscape for the HealthTech and MedTech sectors is projected to undergo a significant recovery in 2026. Following a period of volatility and retrenchment between 2022 and 2024, the confluence of stabilising macroeconomic conditions, investor appetite for disruptive technology and a substantial backlog of highly mature companies suggests that 2026 will be the most active year for public offerings since the market peaks of 2021. However, the market’s discipline is resolute; premium valuations will be reserved exclusively for companies demonstrating superior financial metrics, specifically high gross margins and a clearly modelled path to non-GAAP profitability, signalling the definitive end of the "growth at all costs" investment philosophy. Leading sectors poised for success include Surgical Robotics and AI-enabled Digital Health platforms targeting Value-Based Care (VBC) and operational efficiency. Executive Summary: The 2026 IPO Resurgence Thesis The core forecast for 2026 indicates a resurgence in HealthTech and MedTech IPO activity. This growth is underpinned by key drivers, including anticipated monetary policy easing globally, a notable aftermarket performance of the 2025 IPO cohort, and the maturation of Artificial Intelligence (AI) focused business models. Investment banks are confident, citing a strong pipeline across sectors, including healthcare, extending well into 2026. The primary mandate for success has shifted entirely toward quality. Public markets are demanding companies demonstrate robust financial discipline. This requirement necessitates run-rate revenues that meet heightened thresholds and critically, high gross margins, typically ranging between 60% and 80%. The market will highly favour high-growth, specialised technology firms in surgical robotics and AI platforms that drive measurable cost reductions in areas like clinical staffing and administration. Global Capital Markets Context: Tailwinds and Headwinds for 2026 Macroeconomic Catalysts: The Supportive Backdrop Global IPO market growth is expected to accelerate into early 2026, driven by several supportive factors. Primary among these are expectations of monetary easing across major economies and a marked improvement in market stability and investor confidence. Central banks’ signals of rate stabilisation are critical, providing a conducive backdrop for equity issuance. Investment banking reports cite robust pipelines, including multiple billion-euro offerings in sectors such as healthcare, preparing to launch in early 2026. The United States continues to demonstrate its dominance in global capital markets, maintaining technological leadership and leading global IPO proceeds through the first nine months of 2025. This strong activity, coupled with resilient corporate earnings, underpins a generally bullish sentiment in equity markets. This combination of strong macroeconomic factors and the necessity for private equity and venture capital sponsors to realise liquidity from mature portfolio companies accelerates the exit timeline for high-quality candidates, setting the stage for increased volume and size of IPOs in 2026. The AI-Driven Disruption as a Capital Magnet The IPO market is receiving a significant thrust from investor appetite for companies focused on AI and new technology, particularly within healthcare. AI-driven technological disruption is recognised as a decisive force shaping sentiment and capital flows. Investment management firms are not only exploring AI for internal operational efficiencies but are also actively seeking to expand product lineups into AI-driven investment offerings. However, the enthusiasm is highly nuanced. While AI provides undeniable momentum, public market scrutiny mandates that AI integration must be operationalised to solve high-cost pain points within healthcare, such as administrative complexity, staff shortages and clinical inefficiency. Therefore, successful 2026 IPOs will present AI not merely as a technological feature, but as the core enabler of superior unit economics, proving the underlying technology leads directly to genuine profit assumptions and justifying sustainable long-term valuation. Structural Headwinds and Systemic Risks Despite the broad optimism, the 2026 IPO trajectory faces persistent global and domestic risks. Foremost among these is the pervasive warning regarding an AI-fueled valuation bubble. Financial experts caution that the excitement surrounding AI stocks has become "overheated," increasing the risk of a significant global stock market correction. Historical precedent shows that market concentration, such as the "Magnificent Seven" accounting for 20% of the MSCI World Index, often culminates in market corrections. A generalised correction could severely depress valuations across all sectors, including HealthTech, regardless of individual company performance. Furthermore, persistent geopolitical risks, including global trade headwinds and uncertainty over US tariff policies, continue to challenge market stability. Domestically, potential political instability, such as prolonged government shutdowns or regulatory uncertainty stemming from proposals to cut funding and staff at the Food and Drug Administration (FDA) and Health and Human Services (HHS), introduces an element of unpredictability that could stall IPO momentum, particularly for MedTech companies reliant on regulatory clearances. The Reopening IPO Window: Lessons from the 2024-2025 Cohorts The End of the Digital Health IPO Drought The successful debuts of Hinge Health, Omada Health, and HeartFlow in mid-2025 were pivotal, collectively ending a prolonged drought in digital health IPO activity. Hinge Health's performance set the definitive public market template. The virtual physical therapy company reported second-quarter 2025 revenue of $139 Million (a 55% year-over-year increase), coupled with an exceptional adjusted gross margin of 83% (up from 77% a year prior). Crucially, Hinge Health achieved favourable operating leverage, driving positive non-GAAP operating income of $26.1 Million and positive free cash flow. The performance of these trailblazers confirmed that public markets are prepared to commit capital to digital health, provided the companies exhibit undeniable maturity and financial discipline. This success creates a two-tiered valuation dynamic: companies that meet the 80%+ gross margin benchmark will likely achieve premium valuation multiples by demonstrating strong, defensible SaaS-like unit economics and successful integration with payers and employers. Companies falling below this high bar risk being viewed as offering a commoditized service and may struggle to justify private unicorn valuations. MedTech's Selective Rebound and Performance Variability The MedTech IPO environment also showed tangible signs of improvement in 2025, recording six U.S. device company public offerings within the first eight months, a meaningful increase over the previous year.However, post-listing performance has been highly selective. Of the two MedTech IPOs completed in Q1 2025, Kestra Medical Technologies traded up 43%, while Beta Bionics, focused on diabetes management, traded down 36% from its initial price. In contrast, CeriBell Inc. (point-of-care EEG systems), which went public in late 2024, achieved a 52% gain post-offering, supported by high gross margins (85%) and robust revenue guidance. This variable performance underscores that sector resilience alone is insufficient; investors are highly discerning, prioritising companies that have substantially de-risked their clinical and regulatory pathways and demonstrating strong commercial execution. The market rewards a mature commercial model and high margins over promising, yet commercially unproven, technology. The Public Market Template for 2026 The strong aftermarket performance of 2025 IPOs, specifically, U.S. listings raising over $50 Million delivered median returns exceeding 40% through Q2 2025, is reinforcing investor confidence and creating momentum for the coming year. Critically, the market freeze during 2022–2024 created a substantial backlog of high-quality, mature medical device and health technology companies. Having successfully navigated the extended private market funding cycles, many of these firms are now viewed as exceptionally well-positioned to test the public markets in 2026. These companies must be prepared to demonstrate independence from general market sluggishness by proving highly differentiated technology through metrics such as Return on Invested Capital into R&D (ROIC R&D). MedTech IPO Outlook 2026: Focus on Innovation and Scale The 2026 MedTech IPO market is anticipated to feature a dual structure, characterised by massive "Scale Deals" from established distribution players and high-growth "Innovation Deals" from specialised technology firms, particularly in robotics. Marquee Offerings: The Scale Player Thesis A dominant potential offering for 2026 is Medline Industries, a global distributor and manufacturer with an estimated revenue base of $27–28 Billion in 2025. Medline is targeting a potential $5 billion IPO at a valuation of $50 billion. This listing, if successful, would be a major liquidity event and a crucial test of the public market’s confidence in essential, large-scale healthcare infrastructure. The success of the IPO will hinge on investor belief that cost impacts, such as those related to US tariff policies which affected cash flow in early 2025, are transient, and that normalised cash flow supports a premium valuation multiple. A successful Medline IPO would significantly boost the aggregate capital raised by MedTech companies in 2026. Innovation Segment Deep Dive: Robotics, Diagnostics, and Chronic Care Surgical Robotics & Automation The surgical robotics sector provides a compelling narrative for public market investment, with the global robotic-assisted surgery market projected to reach $14 Billion by 2026, representing an 11% Compound Annual Growth Rate (CAGR). CMR Surgical, a UK-based developer of the Versius surgical robot, is one of the top candidates. Valued around $4 Billion, the company is actively exploring a potential sale or IPO following strategic milestones. Critically, its July 2025 FDA clearance for gallbladder procedures immediately opened the high-value U.S. market, serving as a powerful, immediate catalyst for IPO readiness. This illustrates that for sophisticated MedTech investors, regulatory clearance is a quantifiable financial event, not just a technical hurdle. Globally, the robotics industry has 16 companies in the IPO pipeline spanning various robotics fields, including surgical R&D projects like Sizherui in China. Furthermore, major players like Johnson & Johnson are timing regulatory submission for their Ottava soft-tissue surgical robotics platform for 2026. High-Growth Therapeutics/Diagnostics Investors maintain strong focus on MedTech firms targeting high-growth therapeutic areas, including structural heart, pulse field ablation, and diabetes.The weight-management market, fuelled by the GLP-1 drug phenomenon, remains arguably the hottest therapeutic niche. Companies involved in the development of next-generation oral GLP-1 medicines, such as Structure Therapeutics, are positioned as highly attractive IPO candidates due to the potential for significant upside and competitive differentiation within this massive commercial opportunity. For these high-growth MedTech firms, the IPO readiness benchmarks require run-rate revenues between $40 Million and $60 Million, coupled with expected revenue growth of 25%–30% CAGR over the next two to three years. MedTech 2026 Potential Marquee Offerings and Market Drivers Company (Example) Sub-Sector Latest Status/Target Value Market Driver / IPO Thesis Medline Industries Medical Supply Distribution $50 Billion Target Valuation; $5B Raise Rarity of scale; strong and resilient $27B+ revenue base, liquidity event CMR Surgical Surgical Robotics (Versius) ~$4.0 Billion Potential Sale/IPO Recent US FDA clearance (July 2025) and commercial acceleration in the high-growth $14B market Beta Bionics Automated Diabetes Management Post-IPO: Mixed aftermarket performance Differentiated ease-of-use (iLet system) in a high-growth, under penetrated market Structure Therapeutics Oral GLP-1 Development Biotech/Pharma Focus Capitalising on the high-demand weight-management market with a differentiated oral approach HealthTech/Digital Health IPO Outlook 2026: The Discipline Shift The 2026 HealthTech cohort will consist of companies that have successfully leveraged large late-stage private funding to reach financial maturity, defined by operational efficiency and AI-driven growth. The AI-First Imperative and Operational Efficiency The investment community has moved beyond pure AI hype, now demanding AI tools that offer a clear and quantifiable Return on Investment (ROI) for providers and payers, specifically targeting the reduction of high administrative costs.This commercial discipline heavily favours AI solutions built for operational efficiency. Hippocratic AI exemplifies this shift. Following a $141 Million Series B round in January 2025, the company achieved a $1.64 Billion valuation. It is focused on developing a safe Large Language Model (LLM) for healthcare staffing, deploying AI-powered virtual nurses and care coordinators. The B2B usage-based model directly addresses the massive global staffing crisis, aligning perfectly with the public market's demand for technology that drives immediate cost savings. Furthermore, companies enabling Value-Based Care (VBC) through proprietary data are strong candidates. Innovaccer, a major VBC enabler with a $3.2 billion valuation and significant 2025 funding, capitalises on the fact that 64% of healthcare leaders expect revenue gains from VBC models in 2025, which AI will help to scale efficiently. Similarly, Truveta, a healthcare data and genomics platform, secured $320 Million in Series C funding in January 2025 at a $1 Billion valuation. Its strategic partnerships with major health systems (including Regeneron and Illumina) create a powerful, defensible data moat highly attractive to investors seeking proprietary assets. The convergence of AI capabilities with the VBC business model is emerging as the premier investment theme for 2026, as these platforms function as necessary infrastructure for maximising revenue and minimising overhead in a financially constrained system. The Next Wave of Condition-Specific Digital Health The successful mid-2025 IPOs of Hinge Health and Omada Health have created a clear, repeatable playbook for the next wave of digital health companies: target chronic, high-cost conditions (like MSK, diabetes, and obesity) and monetize through established employer or payer channels with clinically validated outcomes. Key candidates expected to follow this model in 2026 include: Sword Health: A direct competitor to Hinge Health in the digital musculoskeletal space, Sword Health announced a $40 Million funding round in June 2025 at a $4 billion valuation. Its recent expansion into mental health via an "AI Care" model positions it for an imminent public listing to capitalise on Hinge’s positive market signal. Aledade and Thyme Care: Identified as likely candidates, these firms align with the systemic shift toward risk-sharing, focusing on VBC enablement in primary care and value-based oncology care, respectively. While the Digital Therapeutics (DTx) market is projected to grow rapidly, potentially reaching $12.1 Billion by 2026 (a 27.7% CAGR), the path for pure-play DTx IPOs remains complex. Challenges related to reimbursement and stringent clinical validation persist. Success in this sub-segment will be more likely for those companies demonstrating strong B2B adoption and integration into traditional pharmaceutical commercial models, rather than relying solely on direct-to-consumer monetisation. HealthTech/Digital Health 2026 Potential IPO Candidates and Valuation Metrics Company Primary Focus Latest Valuation (2025) IPO Thesis & Readiness Sword Health Digital MSK / AI Care $4.0 Billion Following Hinge Health playbook; leveraging AI expansion and imminent exit pressure Hippocratic AI Generative AI/Virtual Nursing $1.64 Billion Exemplar of AI-first efficiency; strong B2B usage-based model solving staffing crisis Innovaccer Healthcare Data & VBC Tech $3.2 Billion Critical VBC infrastructure enabler; high maturity signaled by large funding rounds Truveta Health Data & Genomics Platform $1.0 Billion Strong proprietary data moat built via strategic health system and life science partnerships Aledade Value-Based Primary Care Late-Stage Private Strong VBC model, alignment with systemic shift toward risk-sharing The Mandate for IPO Readiness: 2026 Financial Benchmarks The diligence requirements for private companies preparing for a 2026 IPO have fundamentally shifted. Investors are no longer focused on measuring potential but rather on proven, scalable and sustainable business models. Revenue Scale and Growth Expectations The required revenue thresholds for a successful public market entry are notably higher than in previous boom cycles. For HealthTech and digital health companies, investors require run-rate revenues exceeding $200 Million, accompanied by expected revenue growth of 20%–25% CAGR over the next two to three years. The high revenue requirement for HealthTech reflects the need for substantial commercial traction in fragmented provider and payer markets. For high-growth MedTech, tools, and diagnostics companies, the minimum revenue bar is slightly lower, demanding run-rate revenues in the $40 Million to $60 million range. However, this sector faces a higher expectation for forward growth, requiring 25%–30% CAGR to justify a premium valuation. MedTech can command a premium at a smaller scale only if the underlying technology is highly proprietary and differentiated, making it less susceptible to commoditisation. Profitability, Margins, and Operating Leverage The single most critical financial hurdle for the 2026 cohort is the gross margin profile. On average, investors expect steady-state gross margins for both high-growth HealthTech and MedTech to fall between 60% and 80%. The remarkable 83% adjusted gross margin reported by Hinge Health sets an exceptionally high bar for digital platforms. Companies must demonstrate clear operating leverage, the ability to stabilise operating expenses relative to rising revenue and highlight a credible path to being EBITDA positive. Hinge Health’s immediate achievement of positive non-GAAP operating income post-IPO solidified this discipline. For innovative MedTech firms, demonstrating the efficient use of capital is also crucial. Investors scrutinise the Return on Invested Capital into R&D (ROIC R&D), which serves as the most critical metric for assuring the market that past investment has yielded differentiable, proprietary technology. Market Moats and Differentiation Beyond core financial metrics, the ability to successfully list and sustain valuation requires demonstrable market defensibility, or a "moat." This includes: Clinical Validation: Companies must move beyond anecdotal success, presenting independent, fact-based clinical data to defend financial projections and mitigate investor risk perception. Proprietary Data and AI: Success is increasingly reliant on possessing strong proprietary "data moats" and scalable business models powered by AI. This applies to HealthTech firms like Truveta, which aggregates vast proprietary clinical data sets and MedTech firms, which leverage data collected from advanced robotic systems, such as J&J’s Ottava platform. The higher financial and operational thresholds observed across both sectors are the direct consequence of companies staying private for longer during the downturn. These elevated standards are now mandatory, as public investors require significant evidence of scale and cost efficiency to deploy capital. High gross margins are a proxy for pricing power, proving that the solution is truly differentiated and non-commoditised. 2026 IPO Readiness Financial Benchmarks by Sector Metric MedTech/Devices (High-Growth) HealthTech/Digital Health Minimum Annual Run-Rate Revenue $40M – $60M+ $200M+ Gross Margin (Target) 65% – 80% 60% – 80% (Hinge Health set the high bar at 83%) Required Growth (Next 2-3 Yrs CAGR) 25% – 30% 20% – 25% Cash Flow/Profitability Clear path to EBITDA positive Must demonstrate non-GAAP Operating Income and/or FCF positive trajectory Conclusion and Strategic Recommendations Synthesis of 2026 Predictions The analysis confirms that the 2026 IPO market for HealthTech and MedTech is expected to accelerate significantly, driven by an improved macroeconomic environment, monetary accommodation, and the disruptive potential of AI in clinical and administrative settings. While the volume of listings may not reach the speculative frenzy of 2021, the overall quality and average deal size are anticipated to be substantially higher. The concentration of high-quality, mature companies in the IPO pipeline, coupled with the potential for mega-listings like Medline, suggests that the total capital raised in 2026 could significantly surpass previous years.This confidence, however, remains brittle and highly vulnerable to systemic risks, including geopolitical events and the potential market correction stemming from an overheated broader AI index. Strategic Recommendations for Private Companies For late-stage HealthTech and MedTech companies aiming for a 2026 public debut, the following strategic priorities are essential: Mandate Profitability: Management teams must prioritise achieving non-GAAP operating income positivity and maximising operational leverage immediately, setting Hinge Health's financial model as the minimum acceptable standard for market entry. Quantify AI’s Commercial ROI: The value proposition of AI integration must be explicitly tied to measurable financial outcomes, such as reduced administrative costs or enhanced VBC performance. General technological novelty is insufficient; demonstrable Return on Investment (ROI) is the new prerequisite for public funding. Strategically De-risk Products: For MedTech companies, the timing of an IPO should be aligned with major de-risking milestones, such as final FDA clearance or robust clinical trial data readout, which serve as direct catalysts for higher valuation and reduced risk perception (eg. CMR Surgical). Risk Monitoring Checklist for Public Investors Investors assessing the 2026 IPO cohort should maintain a rigorous, disciplined approach: Valuation Stress Testing: Valuations, particularly for AI-adjacent companies, must be stress-tested against the potential for a generalised market correction in the broader technology sector in 2026. Margin Sustainability: Demand clear transparency regarding Cost of Goods Sold (COGS) and operational expenditure (OpEx) to ensure the stated 60%–80% gross margin target is not only achievable but sustainable in the post-listing competitive environment. Policy Sensitivity: Closely monitor shifts in U.S. healthcare policy, especially regarding regulatory funding (FDA/HHS) and trade tariffs, as these factors directly impact the manufacturing costs and time-to-market for MedTech issuers. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors @ MedTech and HealthTech events in October, November, December 2025 Nelson Advisors will be speaking, presenting and chairing a number of panels at HealthTech conferences and events in October, November and December 2025. Please feel free to come and meet us in person or to book a meeting with us online please visit https://scheduler.zoom.us/nelson-advisors/meeting October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel https://healthcare-summit.co.uk NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland – Attending the NHS Innovation Accelerator sessions https://nhscepcommunity.com/events/179287 Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel https://www.globalhealthsaudi.com/en/home.html November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel https://impactx2050.com/healthtechx MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards https://med-tech.world/malta December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack: Emerging Vulnerabilities in Healthcare”Panel https://healthtechforward.com HealthInvestor Power List Awards 2025, London, UK – Judging Panel https://healthinvestorpowerlist.com Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

This Week in European HealthTech and MedTech: 17th October 2025 Major developments in European HealthTech this week have been dominated by major funding rounds in biotech, significant regulatory alignment and continued investment in digital health. Here are the key highlights: 1. Record-Breaking Funding Rounds German Biotech Tubulis secured a €308 million Series C financing round. This is reported as the largest Series C ever raised by a European biotech and the largest private financing globally for an antibody-drug conjugate (ADC) developer. The funds will advance their cancer therapies, including a lead candidate in a Phase I/IIa study. Finnish HealthTech Oura (the smart ring maker) raised substantial fresh funding, valuing the company at around $11 billion, and plans to accelerate AI and product innovation globally. British investor Spex Capital announced the first €30 million commitment to its flagship €100 million Venture HealthTech Fund, aimed at global early-stage HealthTech startups. 2. Regulatory & International Cooperation The UK's MHRA (Medicines and Healthcare products Regulatory Agency) and the US FDA (Food and Drug Administration) announced a deeper collaboration on medical technologies and AI. This alliance aims to harmonise regulation and create new reliance routes to speed up safe access to innovative devices in the UK. The EU Data Act's obligations became applicable this week, which is a major regulatory cornerstone designed to unlock the value of data across sectors, including healthcare and life sciences, by establishing rules on data access and use. 3. Product Launches and AI Adoption Medtronic launched its VitalFlow ECMO system in Europe, a new one-system platform for critical care. Vektor Medical secured the CE mark for vMap, an AI-assisted, non-invasive arrhythmia mapping product, allowing its entry into the EU market. There's ongoing focus on AI integration in clinical settings, with reports on major NHS trusts pushing forward with comprehensive AI strategy roadmaps. This Week in European HealthTech and MedTech: 17th October 2025 The last week in European MedTech has been dominated by regulatory and funding activities, as well as continued momentum in digital health and surgical innovation. 🇪🇺 Regulatory News and Policy The central theme continues to be the implementation and potential revision of the EU's Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). Call for Evidence on MDR/IVDR Reform: The European Commission launched a "Call for Evidence" on the future of the MDR/IVDR, seeking feedback on a targeted revision. The goal is to reduce administrative burden, improve predictability, and enable digitalization in the regulations. This consultation was a major focal point for industry last week. Industry Push for Action: Industry group MedTech Europe is actively pushing for immediate regulatory changes by early 2026. Key requests include a targeted postponement of re-certification requirements to avoid regulatory bottlenecks and the creation of a single governance structure for Notified Bodies to ensure a more efficient CE-marking system. UK Regulatory Updates: The UK's MHRA (Medicines and Healthcare products Regulatory Agency) published guidance to help manufacturers prepare for a new device registration fee set to apply from April 1st. They also reported that reforms have more than halved the time it takes to approve clinical trials, falling from 91 days to 41 days. 💰 Funding and Innovation Highlights Several companies secured funding and advanced commercial rollout of innovative technologies: Remote Monitoring: French company RDS secured a €14 million Series A round to industrialise and expand its MultiSense RDS, a CE-marked connected patch for continuous remote patient monitoring across Europe. Cardiology Device Rollout: Elixir Medical began its full European rollout of the LithiX high-capacity Intravascular Lithotripsy (IVL) device following its CE mark. This rollout follows treatment of over 400 patients across 16 countries. AI and Robotics Investment: Medtronic plc announced it is doubling its London presence to establish a global hub for surgical robotics and AI, aligning with long-term health plan ambitions in the UK. AI for Veterinary MedTech: UK startup Lupa raised a €17 million Series A to scale its AI-native operating system for veterinary clinics, demonstrating AI's spread into adjacent healthcare sectors. 🌐 Global & Other European MedTech Updates FDA Inspection Reliance: The European Medicines Agency (EMA) has begun accepting the FDA's findings from inspections of manufacturing facilities conducted outside the US, a significant step toward international regulatory harmonisation. Pharmaceutical Cost Debate: Under the UWWTD's (Urban Waste Water Treatment Directive) extended producer responsibility scheme, pharmaceutical and cosmetics industries will be required to contribute to wastewater treatment costs. This plan has received pushback from major European drugmaker trade groups. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors Partner Lloyd Price has been invited to join the "Health Data Under Attack: Emerging Vulnerabilities in Healthcare” panel at Health Tech Forward 2025 Conference in Barcelona. Health Data Under Attack: Emerging Vulnerabilities in Healthcare The healthcare sector faces a rapidly escalating threat landscape, with data breaches and cyberattacks becoming more frequent, sophisticated, and impactful. The vulnerabilities are often a combination of persistent issues and newly emerging threats.. Some of the key themes expected to be discussed on the panel include: 1. Ransomware and Extortion Attacks Ransomware remains the single most significant threat, often leading to service disruption and data theft. 2. Third-Party and Supply Chain Risk The reliance on an interconnected ecosystem of vendors, business associates, and technology partners has created a major security blind spot. 3. Exploitation of Network and Edge Devices Vulnerabilities in critical network infrastructure are being rapidly exploited by threat actors. 4. Human Factors and Phishing Innovation While not new, social engineering tactics continue to be the most common initial access vector, and they are becoming more advanced. 5. Internet of Medical Things (IoMT) and Legacy Systems The blend of old and new technology in clinical settings creates unique security challenges. 6. Geopolitical and Nation-State Threats Cyber adversaries linked to hostile nation-states are increasingly interested in the healthcare sector for espionage, revenue generation, and disruption. Health Tech Forward 2025 Conference Name: Health Tech Forward 2025 Location: Palau de Congressos de Barcelona in Barcelona, Spain. Dates: December 3-4, 2025. Focus: Europe's premier event for health tech innovation and investment, featuring keynote speeches, dynamic panel discussions, and targeted 1:1 networking opportunities. Panel Topic Context: The panel falls under the track/topic of cybersecurity, compliance, and collaboration(often referred to as the "3C's"), addressing the critical security challenges facing the healthcare sector as it adopts new technologies. The conference agenda often covers themes ranging from AI insights and clinical breakthroughs to consumer tech & wellness. https://healthtechforward.com Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Integrated Health Organisations (IHO's) at the heart of the Department of Health and Social Care (DHSC's) new 10 Year Plan The Department of Health and Social Care (DHSC) in the UK has recently drafted a 10-Year Health Plan that places Integrated Health Organisations (IHOs) at its core. This plan signifies a radical reform in the structure and governance of the NHS, aiming to shift care from hospitals to communities, leverage technology, and prioritise prevention. Here's a breakdown of the key aspects related to IHOs in the DHSC's new plan: What are Integrated Health Organisations (IHOs)? According to a draft of the plan seen by HSJ, the strongest existing Foundation Trusts (FTs) will be allowed to become "Integrated Health Organisations." These IHOs will be given the significant responsibility of managing the entire healthcare budget for a designated local population. This is a concept similar to "accountable care organizations" in the USA. The goal is to avoid the current issue where improving preventative care in one type of provider (e.g., GP practices) doesn't necessarily benefit another (e.g., hospitals), by creating a single entity responsible for the whole pathway of care for a population. Role of IHOs in the 10-Year Plan Devolution and Local Control: The plan emphasizes devolving decision-making to local leaders, with IHOs having substantial autonomy over how care is delivered and budgets are managed for their local populations. Shift from Hospital to Community: A major thrust of the plan is to move care away from traditional hospital settings and into the community. IHOs will be central to this, as they will be responsible for commissioning and integrating services closer to people's homes, including primary care, community health, mental health, and social care. Focus on Prevention: By managing the entire budget for a population, IHOs are incentivized to invest in preventative care and early intervention, aiming to keep people healthier and reduce demand on acute services. Integration of Services: IHOs are designed to break down existing silos between different healthcare providers and social care, promoting person-centred and coordinated care across various settings. This involves fostering closer working relationships between GPs, community services, mental health teams, social care, and the voluntary sector. Accountability for Outcomes: While IHOs will have more autonomy, they will also be held accountable for health outcomes within their designated population. Wider Context of the 10-Year Plan: The plan seeks to achieve three major "shifts": From hospital to community: Greater investment and emphasis on primary and community services. From analogue to digital: Making better use of technology, including AI, and enabling patients to manage their health more effectively through digital platforms like the NHS App From sickness to prevention: Shifting the focus from treating illness to preventing it in the first place, through public health initiatives and early intervention. The plan also aims to speed up clinical trials, make it easier for patients to participate, and restore the UK's position as a global leader in health research and innovation. Governance changes are significant, with elected mayors potentially taking over from local authority leaders on Integrated Care Boards (ICBs), and the DHSC itself taking a more direct role in approving "new FTs" (IHOs). In essence, the DHSC's 10-Year Health Plan envisages IHOs as powerful, locally-led entities with significant control over budgets and care delivery, driving a fundamental transformation towards more integrated, preventative, and digitally-enabled healthcare in the UK. Nelson Advisors > Healthcare Technology M&A Nelson Advisors specialise in mergers, acquisitions & partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions & partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands HIMSS AI in Healthcare > 10-11th July 2025, New York, USA World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Nelson Advisors specialise in mergers, acquisitions & partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Executive Summary: The Structural Pillars of MyChart’s Market Hegemony Thesis Statement: EHR Foundation as the Competitive Moat The sustained market leading position of Epic MyChart is not attributable solely to superior user experience or functionality, but rather represents a direct, structural consequence of Epic Systems’ foundational dominance in the enterprise Electronic Health Record (EHR) market, particularly among large Integrated Delivery Networks (IDNs). This EHR control provides an insurmountable competitive barrier, securing MyChart’s deployment across vast healthcare ecosystems. This foundational leverage, combined with demonstrable operational Return on Investment (ROI), evidenced by metrics such as reduced appointment no-shows and increased revenue cycle efficiency and accelerated adoption driven by regulatory mandates like the 21st Century Cures Act, creates a powerful competitive moat that effectively marginalises both EHR-tethered rivals and standalone patient portal solutions. Key Findings Snapshot The market leadership of MyChart is defined by unparalleled scale and quantifiable performance: Foundation: Epic controls 37.7% of the acute care hospital EHR market and an impressive 43.92% of the ambulatory sector. This institutional reach ensures MyChart is the default patient engagement layer for nearly half the U.S. outpatient market. Operational ROI: MyChart use was demonstrably associated with 21 Million fewer appointment no-shows across 1.6 billion outpatient visits analysed in 2024. This translates directly into maximised clinical utilisation and efficiency gains for health systems. Competitive Edge: Epic maintains superior strategic alignment with its customers, leading KLAS patient engagement rankings, with 70% of users viewing the vendor as best aligned with their long-term engagement goals due to its integration and partnership model. The Strategic Context: Epic’s Foundational Dominance in EHR Quantification of Core Market Share and IDN Strategy Epic Systems has solidified its position as the undisputed market leader in the U.S. hospital EHR space, underpinning the success of MyChart. Current data confirms Epic commands 37.7% of the acute care hospital EHR market, a figure that represents substantial recent growth, rising from 28% in 2019. More critically, the company’s dominance extends into the outpatient environment, where it holds a commanding 43.92% market share in ambulatory care. The scale of this dominance is further magnified by strategic wins. In 2024, Epic achieved its largest net gain on record, adding 176 hospitals, and now holds an estimated 42.3% of the overall US acute care hospital market share, representing control over 54.9% of the nation’s acute care bed market. This growth is largely driven by a focused strategy on serving larger health systems and Integrated Delivery Networks (IDNs) seeking comprehensive tools for streamlined operations and integrated care. The Structural Advantage: MyChart as a Bundled Asset MyChart’s leadership is structurally guaranteed because it is the native, tethered patient portal for the Epic EHR. In any institutional procurement decision involving Epic, MyChart is automatically selected as the default patient engagement layer, eliminating the need for a separate competitive analysis or costly integration project for the portal component. This inherent lock-in mechanism creates an enormous strategic advantage. The fact that Epic controls nearly 44% of the ambulatory market means it dictates the workflow for new appointments, results delivery, and critical communication in a significant portion of the U.S. outpatient sector.This foundational control over the clinical workflow makes it strategically impractical for any specialised, standalone patient portal—regardless of superior functional design or user experience, to achieve meaningful enterprise scale without integrating deeply into Epic’s proprietary system. Consequently, MyChart’s market security is ultimately derived from institutional purchasing decisions based on stability, comprehensive integration and interoperability reputation, rather than purely patient adoption metrics alone. Furthermore, Epic’s strategy includes the Community Connect program, which enables smaller, standalone hospitals to affiliate with larger Epic health systems, securing wins in the small hospital market in 2024. This approach constantly expands the institutional footprint, organically increasing the MyChart user base and reinforcing the overall network effect. Market Criticality and Resource Intensity The dominance of Epic is particularly significant when considering the high-acuity market. Epic holds 54.9% of the US acute care bed market share.This metric is crucial because it signifies that Epic handles the clinical data for the most complex, resource intensive and highest-acuity patient populations. As a result, the MyChart platform, which includes components like MyChart Bedside for inpatients, is elevated beyond a simple consumer convenience application. It becomes an indispensable and critical clinical communication tool integrated into core inpatient workflows. This necessity further deepens the competitive moat against vendors focused solely on lighter-touch ambulatory engagement solutions. MyChart as the Integrated Digital Front Door Core Functional Pillars and Seamless Workflow Integration MyChart is positioned as the health system’s essential "digital front door," providing a centralised hub for patients to manage their care journey. This encompasses multiple touch points for both new and existing patients, offering estimates, scheduling, registration, and bill payment capabilities. Key administrative tools streamline operations and improve patient access. These include online appointment scheduling, secure asynchronous messaging with the care team, the ability to request medication refills, and completing pre-visit check-in forms digitally. The system efficiently manages patient flow by offering automatic notifications when an earlier appointment slot becomes available, thus bypassing traditional staff-heavy processes like phone calls and front-desk coordination. Furthermore, compliance with the 21st Century Cures Act mandates the expansion of "Open Notes," requiring the timely release of finalised clinical notes via MyChart, which increases the portal’s transparency and informational utility for the patient. Advanced Ecosystem Features and Longitudinal Care MyChart’s competitive differentiation lies in its advanced ecosystem features, designed to support longitudinal and multi-system care management. Interoperability and Centralisation The platform includes two powerful features addressing patient friction across fragmented health systems: MyChart Central: This hub addresses the consumer pain point of managing disparate patient records by providing a single Epic ID and login, allowing patients to manage their care across multiple organisations that utilise Epic.s This strategic move turns Epic’s widespread, decentralised enterprise adoption into a streamlined, centralised user experience advantage. This proprietary convenience strategically neutralises patient frustration that might otherwise drive demand for third-party aggregation tools, reinforcing patient retention within the Epic ecosystem. Share Everywhere: For care received outside of the Epic network, this feature allows patients to generate a one-time, web-based view of their health record, ensuring seamless care continuity with any provider who has internet access. Continuous and Inpatient Care Management The platform supports ongoing patient management across various settings: Remote Patient Monitoring (RPM): This enables continuous care by tracking key patient health data from home, providing near real-time data flow back to the care team for proactive intervention. MyChart Care Companion: This tool integrates with home monitoring devices to monitor patient progress, delivering notifications and guidance to help patients adhere to their prescribed care plans and improve outcomes. The integration of RPM transforms the portal from a purely historical record viewer into an active, proactive clinical dashboard, essential for managing chronic conditions and securing reimbursement under value-based care models. MyChart Bedside: While admitted to the hospital, patients use this feature for real-time access to their care plan, health information, care team roster, and educational materials. Summary of MyChart’s Core Competitive Features Strategic Category MyChart Feature Impact on Market Leadership Enterprise Interoperability MyChart Central, Share Everywhere Facilitates single patient view across multiple health systems, increasing patient retention and convenience. Digital Health Integration Remote Patient Monitoring (RPM), Care Companion Supports continuous, proactive chronic care management outside the clinic, extending the platform's utility beyond episodic care. Operational Efficiency Online Scheduling, E-Check-in Reduces staff burden, eliminates phone tag, and improves appointment utilisation rates. Financial Engagement Price Transparency, Patient Financial Experience Meets regulatory mandates and streamlines revenue cycle management, integrating billing directly into the patient engagement loop. Financial Transparency and Revenue Cycle Integration A critical strategic function of MyChart is its integration with the financial operations of the health system. The platform offers Price Transparency and a comprehensive Patient Financial Experience, which are essential components for regulatory compliance and meeting contemporary patient consumer expectations. For revenue cycle management, MyChart allows patients to make payments and manage bills. Furthermore, it supports deep integration with advanced payment solutions, such as Bank of America’s Healthcare Payment Solutions (HPS), offering modern options like Apple Pay and Google Pay, and utilising features like HealthLogic to auto-post collections, significantly reducing manual reconciliation work. Quantifiable Impact: Operational Efficiency and Economic ROI Epic MyChart secures its market position not just through features, but through delivering measurable operational efficiency and economic return for health systems. Reducing Patient No-Shows and Improving Clinic Utilisation The most impactful metric validating MyChart’s utility is its effect on patient adherence. Research published in 2024, analysing over 1.6 Billion in-person outpatient visits, found that MyChart use was associated with an estimated 21 Million fewer appointment no-shows in a single year. Patients with an active portal account demonstrated a no show rate of 6.2%, significantly lower than the 7.9% rate observed for patients without an account, a 21.5% relative reduction in the likelihood of a missed appointment. This efficiency gain translates directly into improved clinic management and resource allocation. The reduction equates to approximately 1,700 fewer no-shows per 100,000 scheduled visits among portal users. Such a significant decrease in missed appointments ensures more timely care, optimises provider schedules and directly contributes to greater operational efficiency for the implementing organisation. Demographic Nuance in ROI Analysis reveals that the platform is particularly effective in engaging critical patient demographics. The greatest percentage point difference in no-show rates was observed among the 50–64 age group, where users exhibited a 6.2% no-show rate compared to 8.7% for non-users (a 2.5% point difference). In contrast, the smallest difference was noted among 18–34-year-olds (9.3% vs. 10.9%). Operational Impact of MyChart Use on Appointment Adherence (2024 Data) Patient Group No-Show Rate with Active Portal No-Show Rate without Active Portal Difference (Percentage Points) Overall Patient Population 6.2% 7.9% 1.7 Age 50–64 (Highest Difference) 6.2% 8.7% 2.5 Age 18–34 (Smallest Difference) 9.3% 10.9% 1.6 Source: Epic Research 2024 The fact that the most significant operational benefit occurs in the 50–64 age cohort is highly valuable from a risk management perspective. This demographic typically manages more complex chronic conditions, utilises specialists more frequently, and benefits most from a unified organisational aid for managing multi-faceted care plans. MyChart’s proven ability to drive meaningful engagement and adherence within this high-utilisation group affirms its strategic importance for improving population health outcomes and managing financial risk effectively. Enhancing Self-Pay Collections and Revenue Cycle Management Beyond clinical efficiency, MyChart drives measurable improvements in revenue cycle management. A documented case study reported that after implementing MyChart, a health system increased its self-pay collections significantly in the first year. Specifically, the system collected an average of $10.5 Million for hospital billing and $6 Million for professional billing from self-pay patients per month. This represented a 21% and 15% increase, respectively, over the preceding four-year average. This verifiable financial uplift, derived from improved collections and reduced administrative burden through features like auto-posting is the ultimate operational justification for a health system's continued investment in the platform. When a Chief Information Officer evaluates the feasibility of replacing the core EHR, they must also consider the cost of destabilising this proven, quantifiable revenue engine. The proven ROI delivered by MyChart generates a massive financial penalty for system defection, effectively reinforcing the vendor lock-in created by the underlying EHR technology. Competitive Dynamics and Strategic Threats Performance Comparison in the Patient Engagement Market Epic MyChart maintains a leading position in customer satisfaction and alignment. According to healthcare analytics firm KLAS, Epic continues to lead the patient engagement technology field. Surveys indicate that 70% of Epic users consider the vendor to be strongly aligned with their organisation's patient engagement goals. Customers consistently cite the platform's comprehensive, highly integrated functionality, Epic's strategic partnership approach and continuous enhancement roadmap as key factors driving this confidence.This high degree of satisfaction means Epic users exhibit high loyalty and are more likely to continue investing in the vendor’s all-in-one platform. Competition from EHR-Tethered Rivals Major EHR competitors are actively attempting to challenge MyChart’s lead by upgrading their tethered portal solutions: Oracle Health (Cerner): Following the $28.3 Billion acquisition of Cerner, Oracle Health is leveraging its massive technical scale and enterprise platform capabilities to position its portal as a "true digital front door." This involves centralising patient communication, financial transparency, and care coordination capabilities. However, despite technological optimism surrounding the Oracle enterprise fusion, Oracle Health experienced a challenging year in 2024 in terms of market retention. Meditech: Meditech, another major acute care vendor (13.2% market share), has also invested heavily, launching an enhanced integrated patient portal in April 2024 designed for real-time data sharing and improved user experience. Comparative studies often implicitly highlight MyChart’s effectiveness; for instance, portal users in one study (using MyChart) were found to have a reduced no-show rate of 4.7% compared to 12.4% for non-users. The Challenge from Standalone Digital Front Door Solutions (Point Solutions) While MyChart excels in core clinical and administrative integration, the KLAS report identifies functional gaps. Specifically, more than one-third of Epic clients reported supplementing MyChart with third-party tools. These gaps typically involve specialised areas such as advanced communication, patient education content, and sophisticated survey functionality, where vendors like Artera and NRC Health are seen filling key roles. The market features a growing array of niche competitors offering specialised digital front door solutions, including platforms for referral management (ReferralMD), optimised scheduling (Kyruus Health, Solv), digital front door orchestration (Orbita.ai, DexCare), and adaptive call centre automation (Hyro). These point solutions may offer superior user experiences or deeper functionality in narrow areas, but they ultimately lack the native, deep integration into clinical documentation and core workflows that MyChart maintains. This competitive dynamic leads to a situation where MyChart remains the "good enough" core platform that orchestrates the ecosystem, securing control over mission-critical data flows (chart access, results, core scheduling, billing). The specialised supplements serve as tactical enhancements rather than strategic replacements, maintaining Epic’s monopolistic gravity over the patient engagement layer. Regulatory and Technological Vectors for Future Positioning The 21st Century Cures Act and Regulatory Tailwinds Regulatory intervention has provided a significant tailwind for Epic MyChart. The 21st Century Cures Act, specifically the expansion of the "Open Notes" initiative starting in late 2023, requires providers to ensure applicable, finalised medical information, including additional clinical notes, is readily available to patients via portals like MyChart. This mandate effectively forces health systems to not only implement a portal solution but also ensure high functionality and wide patient utilisation, as failure to provide timely electronic access constitutes information blocking. For the vast Epic community, this mandate naturally accelerates the activation and usage rates of MyChart, reinforcing its dominant usage simply through regulatory compliance requirements. Interoperability Standards (FHIR and SMART on FHIR) Epic, along with other enterprise EMRs, has actively integrated support for the Fast Healthcare Interoperability Resources (FHIR) standard through Health Information Exchanges (HIE). This compliance, coupled with the implementation of SMART on FHIR (Substitutable Medical Apps, Reusable Technology), enables the creation of a modular healthcare ecosystem where third-party developers can build specialised applications that connect and utilise Epic’s FHIR resources. While FHIR standards are often perceived as a mechanism to loosen vendor lock-in by commoditising data access, Epic strategically embraces it. By enabling innovation on top of the Epic platform, the company ensures that MyChart remains the central hub controlling the core patient data flow, rather than seeing innovation occur outside of its environment. This allows flexibility while maintaining the platform’s central gravity. However, the expanding FHIR ecosystem presents security challenges for third-party mobile applications, some of which have been found to contain hardcoded API keys that could potentially be used to attack EHR APIs, though Epic's own FHIR servers have historically shown strong security. Persistent Barriers to Meaningful Portal Adoption Despite MyChart’s high effectiveness in driving operational ROI, persistent market barriers prevent universal and meaningful adoption across the patient population. Overall acceptance of patient portals lags, with data indicating that usability remains a challenge. Patients often struggle to navigate interfaces due to confusing medical terminology, poor layout, and information overload. Furthermore, a lack of digital and health literacy, as well as language limitations, continues to hinder effective involvement for certain patient cohorts. Data shows that while 60% of adults reported accessing their portal at least once in 2022, many only used it occasionally. This disparity between initial access and sustained, meaningful usage underscores a fundamental market challenge. MyChart’s demonstrated success in reducing no-shows among complex, high-utilization age groups suggests that its integration depth and broad feature set successfully overcome these barriers better than competing solutions, translating initial access into continuous clinical utility. AI Integration as the Next Phase of Lock-in Looking forward, Epic’s strategic position is being strengthened by its deep integration of Artificial Intelligence (AI) tools aimed at boosting clinical efficiency and patient engagement. Control over massive, longitudinal patient datasets, the "critical asset" for AI development, is the basis for sustained competitive advantage.Since MyChart serves as the primary custodian for patient-generated health data (including RPM feeds, secure messages, and scheduling preferences), leveraging this AI innovation will inherently occur first and most effectively within the MyChart environment. This convergence of data control and AI innovation is expected to create the next generation of competitive advantage rooted in personalized engagement and automated efficiency, further solidifying the strategic relationship between Epic and its client base. Conclusion and Strategic Recommendations Summary of Market Leadership Drivers Epic MyChart’s market dominance is a strategic reality anchored by three fundamental, mutually reinforcing pillars: Structural Market Leverage: Epic’s overwhelming EHR footprint, particularly the 43.92% control of the ambulatory market, ensures MyChart is integrated into the core clinical and operational identity of the nation’s largest health systems. Quantifiable Economic ROI: The platform delivers demonstrable financial and operational gains, proven by $10.5 Million self-pay collection increases and a documented 21 Million reduction in no-show appointments annually. This ROI creates a powerful financial deterrent against vendor switching. Functional Breadth and Ecosystem Design: Features like MyChart Central and integrated Remote Patient Monitoring transform the platform into a sophisticated longitudinal care management hub, while adherence to mandates like the Cures Act continually reinforces its necessity. Strategic Recommendations for Health System CIOs and CSOs For organisations utilising Epic MyChart, maximising the platform's value requires a refined strategic focus: Maximise Ecosystem Investment: Prioritise resources toward maximising patient activation and meaningful utilisation of MyChart features that offer the highest proven ROI, such as integrated financial tools and proactive scheduling management. Special effort should be directed toward optimising engagement within the high-value 50–64 patient demographic, where the platform has demonstrated the greatest proportional success in clinical adherence. Strategic Supplementation Management: While MyChart provides the robust core, its functional gaps in specialized communication or education may require external support. CIOs should adopt third-party point solutions only where the quantifiable return on specialised functionality clearly exceeds the complexity and cost of maintaining integration with the core Epic system. These supplements must be viewed as tactical enhancements, not as foundational components of the digital front door strategy. Prepare for AI-Driven Engagement: Health system leadership must recognise the data generated by MyChart (including RPM feeds and interaction metrics) as the critical asset for future AI initiatives. Strategy should focus on optimising data hygiene and usage within the MyChart environment to ensure the organisation can effectively leverage Epic’s continued AI innovation, securing long-term operational value. Leverage Centralisation: Actively promote the use of MyChart Central to improve the patient experience across affiliated and multiple Epic organizations. This proprietary feature is a key differentiator that improves patient loyalty and reduces frustration in fragmented care settings. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Five Megatrends and Predictions for European HealthTech and MedTech in 2026 The European HealthTech Inflection Point of 2026 This report provides strategic foresight into five dominant mega trends shaping the European HealthTech and MedTech landscape for 2026. The year marks a critical nexus where groundbreaking technological acceleration meets definitive regulatory enforcement, primarily through the EU AI Act and the European Health Data Space (EHDS) regulation. Success in 2026 will be defined by strategic regulatory compliance, the adoption of interoperable data standards (Observational Medical Outcomes Partnership, or OMOP, and Fast Healthcare Interoperability Resources, or FHIR), and the effective leveraging of EU strategic funding (European Defence Fund, or EDF, and Strategic Technologies for Europe Platform, or STEP). The analysis predicts a decisive shift toward Regulatory Infrastructure Plays (Dynamic Consent and Data Flow solutions) and Clinically Validated, High-Growth Disruptors (Pulsed-Field Ablation, Ambient Clinical Intelligence). The primary strategic imperative for executives operating in this ecosystem will be efficiently transforming regulatory burden into a potent competitive filter and an M&A catalyst, separating scalable innovators from regulatory-strained ventures. The European HealthTech Ecosystem: Navigating the 2026 Regulatory Convergence The Shifting Investment Paradigm: From Deal Volume to Capital Efficiency Investment in Europe's Healthcare and Life Sciences sector, particularly within MedTech, continues on an accelerating trajectory, fundamentally driven by innovation in digital health, Artificial Intelligence (AI), and advanced diagnostics. The European Union has strategically catalysed this progress through key initiatives such as the European Health Data Space and the Digital Decade, allocating over €16 billion toward Life Sciences digitalization across its Member States. Market sentiment among investors indicates a growing optimism for increased deal volumes moving into 2026. However, this positive outlook is balanced by a maturation in market activity. Deal flow is consolidating, with a pronounced shift towards fewer, yet significantly larger, transactions. Investors are increasingly favouring scalable technologies that have robust clinical validation. This strategic focus is reinforcing confidence in the region’s innovation ecosystem, evidenced by the fact that 71% of the top-funded MedTech companies in Q2 2025 were based in Europe. For founders and investors in 2026, the market mandate is clear: solutions must demonstrate tangible and measurable value. This means moving beyond novel technology demonstrations to proving documented improvements in patient outcomes, clear cost reductions, or substantial operational efficiencies for constrained healthcare systems. Furthermore, in an environment of tighter capital markets, startups must emphasise capital efficiency, exhibiting a sustainable business model and a clear path to profitability to attract and retain investment. MedTech Europe, representing the industry, actively seeks to influence policy to remove barriers to commercialisation and diffusion through proposed instruments like the European Innovation Act. Advocacy calls specifically for measures that streamline pathways from research to market, improve access to finance for late-stage validation, and promote innovation-friendly public procurement practices to ensure that new technologies rapidly benefit patients across the Single Market. The Dual Regulatory Challenge: Sustained MDR Complexity versus New AI/Data Frameworks The European MedTech sector operates under a persistent dual regulatory challenge. Firstly, significant legal and commercial hurdles stem from the regulatory reforms dictated by the Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR). The transition phase remains complex, with deadlines staggered through 2027–2029, characterized by a system-wide shortage of Notified Bodies, forcing companies to manage persistent regulatory complexity. Secondly, this established friction is now compounded by the introduction of seminal new regulatory frameworks governing AI and data utilization. Europe’s regulatory philosophy, which emphasizes ethics and privacy (GDPR, EU AI Act), creates a marked strategic divergence from the United States' more pro-innovation approach (such as the FDA’s Predetermined Change Control Plan for iterative AI devices). This difference subjects European MedTech innovators to a heavier, dual-certification requirement, where devices often need conformity assessment under both the MDR and the nascent AI Act. MedTech Europe is actively working with EU policymakers, advocating for the simplification of digital legislation to eliminate duplicative or conflicting obligations that impose unnecessary regulatory and administrative burdens. The convergence of high regulatory cost and technical complexity inevitably acts as a competitive filter within the European market. The high fixed costs associated with concurrent compliance across multiple complex regimes (MDR/IVDR, AI Act, EHDS) disproportionately strain undercapitalized small and medium-sized enterprises (SMEs). This scenario inevitably accelerates strategic acquisitions by larger, multinational incumbents (such as Medtronic or Philips) that possess the necessary internal compliance infrastructure and legal resources to absorb these costs efficiently.This process secures innovative technologies for the industry giants while simultaneously consolidating market share, transforming what appears to be regulatory friction into a powerful structural advantage. Critical Policy Timelines: The March 2026 Nexus (EHDS and AI Act Application) The year 2026 represents a definitive inflection point for European HealthTech, anchored by two massive regulatory shifts applying in March.The EU AI Act begins full enforcement for high-risk systems in March 2026. This landmark legislation mandates that AI systems categorised as high-risk—a group that includes much of the complex diagnostic and therapeutic software as a medical device (SaMD) solutions, must comply with strict requirements. These requirements cover data governance, transparency, human oversight, continuous monitoring, and accuracy. Regulatory sandboxes, such as those provided by TEF-Health, are being deployed to help innovators ensure that their products meet these new safety and regulatory requirements, including those of the AI Act and the Medical Device Regulations. Concurrently, the European Health Data Space (EHDS) regulation applies from March 26, 2026. This regulation formalises and significantly broadens the digital sharing of health information across borders, commencing a legal obligation for data holders to share electronic health data for secondary purposes, provided certain conditions are met.The EHDS will govern data access, which will be managed via newly established Health Data Access Bodies (HDABs).This massive flow of data is further enabled by the expansion of the European Electronic Health Record Exchange Format (EEHREF), which is set to widen its scope by 2026 to include imaging and laboratory results. This expansion dramatically increases the volume and complexity of primary use data eligible for secondary use under EHDS, establishing lucrative new revenue pools for secure identity and consent-management solutions that can facilitate cross-border data flow. The combined application of the EU AI Act and the EHDS, paired with the ongoing financial commitments from the European Defence Fund (EDF), provides a definitive framework for the development, deployment, and utilisation of digital health technologies in the coming years. Key Regulatory and Policy Deadlines Shaping European HealthTech in 2026 Policy / Regulation Key 2026 Status / Timeline Impact on Megatrends EU AI Act (High-Risk Systems) Full enforcement begins March 2026, requiring stringent conformity assessments ACI, Electric Medicine, Defence Medtech (AI components) European Health Data Space (EHDS) Regulation Application begins March 26, 2026, mandating data access for secondary use Dynamic Consent Models, ACI data flow, Sleeptech data standards European Defence Fund (EDF) Work Programme Allocations for Alliance for Defence Medical Countermeasures Defence Medtech R&D, Dual-use technology financing European Electronic Health Record Exchange Format (EEHREF) Scope widens to imaging and laboratory results Dynamic Consent Model utility, ACI integration, cross-border care Mega Trend 1: Electric Medicine (Bioelectronics) — Market Dynamics and Clinical Breakthroughs Defining Bioelectronic Medicine: From Neuromodulation to Closed-Loop Devices Bioelectronic medicine, often referred to as electrotherapy, has roots dating back to the 19th century and has evolved significantly since the implementation of devices like the pacemaker. The core technology leverages advanced medical devices, frequently implantable, to enhance or suppress the activity of the nervous system for therapeutic purposes, a field known as neuromodulation. Initial breakthroughs involved stimulating large nerve fibers, such as in the dorsal columns of the spinal cord for chronic pain, and implementation of Vagus Nerve Stimulation (VNS). The current innovation trajectory is moving rapidly toward personalized, closed-loop systems. Future devices are conceived to integrate highly sensitive biosensors and advanced bioanalytical tools capable of continuously monitoring internal physiological parameters. These devices will then respond in real-time to adjust the electrical treatment delivery based on individual needs. This prospect promises a significant leap forward in both treatment efficacy and safety, essentially utilising electrons to replace or augment traditional pharmacological interventions. Historically, Europe has been noted as a significant center for activity and publication in bioelectronics, claiming 43% of publications in a 2009 survey, suggesting a strong foundational expertise in the field. Explosive Market Growth: The Case Study of Pulsed-Field Ablation (PFA) The immediate commercial readiness and disruptive potential of certain electric medicine subsegments are dramatically illustrated by the performance of Pulsed-Field Ablation (PFA) devices. These devices are identified as the fastest-growing segment in the medical device market, projected to achieve a staggering Compound Annual Growth Rate (CAGR) of 80.7% between 2023 and 2028. This hyper-growth, predominantly driven by applications in cardiology (specifically, the treatment of atrial fibrillation), confirms the significant clinical and commercial appetite for advanced electric medicine solutions that offer precision and efficiency. Major global MedTech incumbents are keenly focused on this area. Medtronic, the largest medical device company by annual revenue (approximately USD 32.4 billion), is strategically positioned to capitalise on and consolidate innovation in these high-growth, high-value interventional fields. European Innovation Leadership: Startups and the Graphene Interface European startups are actively pioneering the next generation of neural interfaces and bioelectronic systems. A key example is the Barcelona-based startup Inbrain Neuroelectronics, founded in 2020, which is developing an ultra-thin graphene brain-computer interface. This technology aims to treat complex neurological conditions such as Parkinson’s disease, epilepsy, and stroke, representing a significant scientific frontier in personalized medicine. This firm has attracted substantial financial backing, including selection for the European Innovation Council (EIC) Accelerator programme and securing a large Series B round with EIC participation. The rapid market validation demonstrated by PFA technology, with its projected 80.7% CAGR, provides a high-velocity, near-term revenue stream for the MedTech sector globally. However, the sustained long-term strategic value for Europe lies in highly complex, expensive research areas such as graphene Brain-Computer Interfaces (BCIs). The strategic challenge for these innovators is balancing immediate commercial returns with the sustained investment required for complex BCI research and development, particularly while navigating the regulatory landscape. This involves securing MDR device approval while simultaneously fulfilling the stringent data governance, reliability, and explainability requirements stipulated by the EU AI Act for the device's algorithmic and control systems. Therefore, investment strategies must deliberately balance opportunities providing immediate high returns, like PFA, with the long-term, high-impact R&D, often necessitating the strategic leveraging of EU funding mechanisms detailed in Section V. Market Opportunity and Growth Vectors for Identified Trends (2026 Focus) Mega Trend Projected Growth Driver / Opportunity Key Innovation Metric Source Reference Electric Medicine PFA devices (Cardiology/Electrophysiology) driving clinical disruption PFA projected CAGR of 80.7% (2023-2028) Various Sleeptech Integration into chronic care pathways (RPM) and high-value wearables Global market forecast of $68.78 Billion by 2032 (CAGR 16.7%) Various Ambient Clinical Intelligence Automation of unstructured data capture (80% of clinical data is unstructured) Corporate investment in Gen AI (Philips, Nuance DAX); 90% of informatics pros investing in Gen AI Various Dynamic Data Consent Regulatory catalyst for secondary data monetization in EHDS secure environments EHDS mandates standards (OMOP/FHIR) for data discoverability Various Defence Medtech Civil-military synergy and strategic resilience in critical supply chains EDF 2025/2026 specific actions for Alliance for Defence Medical Countermeasures Various Mega Trend 2: Sleeptech — Expanding from Wellness to Clinically Validated Care Consumer vs. Clinical Segments: Market Scale and Wearables The Sleeptech industry is experiencing rapid expansion, driven by both consumer interest and clinical need. The global sleep tech devices market is forecast to reach $68.78 Billion by 2032, reflecting a significant CAGR of 16.7%. This growth is heavily influenced by societal factors, including the high prevalence of sleep disorders and the rising incidence of depression and anxiety. The wearables segment is highly dominant within this market, with consumer technology giants playing a central role.Wearable device shipments reached 534 million units in 2024, demonstrating broad consumer acceptance. Crucially, high-value wearable devices are successfully blurring the boundary between basic wellness tracking and the continuous collection of patient-generated health data (PGHD). Key players spanning both clinical and consumer realms include ResMed, Koninklijke Philips N.V., Fitbit (owned by Google), Garmin, and European specialists such as Oura Health and Withings. Integration with Remote Patient Monitoring (RPM) and Chronic Disease Management The strategic pivot for the European Sleeptech sector involves transitioning from a direct-to-consumer (D2C) sales model to securing B2B clinical reimbursement via integration into Remote Patient Monitoring (RPM) systems. This is particularly relevant for chronic disease management, where continuous, accurate sleep and physiological data can yield measurable clinical outcomes. For Sleeptech data to be clinically actionable, trustworthy, and eligible for reimbursement within structured European healthcare systems, it must be integrated seamlessly with Electronic Health Records (EHRs). This requires strict adherence to the interoperability standards mandated by the EHDS, which applies from March 2026. Compliance necessitates the broad adoption of FHIR for data exchange and OMOP for semantic clarity and common data model use, ensuring that data is discoverable and interpretable across disparate health systems. The fundamental market dynamic for European Sleeptech moving into 2026 is that success is no longer contingent solely on device accuracy or user experience, but on regulatory compliance and interoperability. EHDS compliance thus functions as a "monetization gate." Companies that invest early and effectively in conforming their proprietary data formats to standardized FHIR/OMOP models will unlock access to valuable clinical pathways and future secondary use revenue, while those that fail to standardize will find their data isolated and commercially limited. Mega Trend 3: Ambient Clinical Intelligence (ACI) — Generative AI and the Documentation Crisis Technology Overview: ACI, Generative AI, and the Documentation Crisis Ambient Clinical Intelligence (ACI) represents a transformative application of generative AI and conversational Natural Language Processing (NLP) in clinical settings. ACI solutions, exemplified by systems like Nuance DAX Copilot, are designed to ambiently listen to multi-party patient-provider conversations, capture them securely, and automatically generate specialty-specific, structured clinical summaries at the point of care. These speech-to-text technologies are capable of achieving transcription accuracies as high as 99%. This technology is deployed to solve one of healthcare's most pressing challenges: the documentation crisis. Up to 80% of existing medical data is unstructured, making insight extraction and analysis manually difficult. ACI alleviates the administrative burden on clinicians, enhances EHR usability, and improves satisfaction by allowing providers to focus on the patient rather than the screen. The efficiency gains support the Quadruple Aim by freeing up clinician time and potentially accelerating healthcare transformation. Global investment confirms the immediate impact of this trend, with over 90% of healthcare informatics professionals worldwide already investing in or planning to invest in generative AI within the next three years. Corporate Battleground and European Deployment The deployment of ACI solutions across Europe is dominated by major technology and health corporations. The Microsoft/Nuance partnership is a front-runner, leveraging the Dragon Ambient eXperience (DAX) Copilot, which is built on Microsoft Azure and utilizes advanced generative AI. DAX is known for its deep integration capabilities with existing Electronic Health Records (EHRs), such as Epic and Cerner, aiming for enterprise-wide deployment focused on significant documentation reduction. Similarly, Royal Philips is strategically accelerating its cloud adoption across Europe through its HealthSuite Imaging solutions on Amazon Web Services (AWS). Philips has explicitly focused its innovation strategy on exploring generative AI capabilities for conversational and ambient reporting, particularly in radiology, recognizing Gen AI as crucial for mitigating staff shortages and escalating costs. Early pilot programs for AI-enabled clinical documentation transcription software have shown positive feedback from providers. However, for ACI to achieve its full potential in Europe, best practices emphasise requiring patient consent workflows, robust change management strategies, and seamless, deep integration with EHRs to ensure scalability and measurable quality outcomes. Regulatory Gateway (2026): ACI as a "High-Risk" System under the EU AI Act The adoption curve of ACI in Europe is inextricably linked to the enforcement of the EU AI Act beginning in March 2026. As AI-based software specifically intended for medical purposes (e.g., diagnostics, decision support), ACI systems are categorized as "High-Risk" under the Act. Compliance requires ACI providers to demonstrate exceptional commitment to several strict regulatory mandates: robust data governance, the use of high-quality training datasets, establishing clear user information protocols, ensuring continuous accuracy, and maintaining systems for human oversight. Transparency and auditability are paramount; advanced ACI solutions are already incorporating features like "Linked Evidence," which maps every line of the generated note back to the original audio transcript for auditing purposes. ACI solutions face a unique regulatory challenge that converges the requirements of two separate 2026 regulations. The system must meet the high standards for algorithmic governance mandated by the AI Act (accuracy and explainability) while simultaneously ensuring that the structured clinical data it generates is standardized (FHIR/OMOP) and legally shareable for secondary use under the EHDS framework. This dependence on dual regulatory compliance for market access and utility creates a significant barrier to entry, heavily favouring multinational corporations like Microsoft (Nuance) and Philips that possess both the extensive capital and the established regulatory infrastructure to navigate this complexity efficiently. Mega Trend 4: Defence Medtech — Dual-Use Technology and Strategic Investment Strategic Context: The ReArm Europe Plan and Societal Resilience Mandate Defence Medtech has emerged as a crucial area of strategic investment, anchored by the European Union's broader geopolitical response encapsulated in the ReArm Europe Plan. This initiative is designed to strengthen Europe's defence technological and industrial base by strategically channeling EU funding towards defence and security. Crucially, the scope of "defence technologies" has been deliberately broadened by policymakers. MEPs have extended the definition to encompass societal resilience, which includes vital areas such as critical infrastructure protection and disaster response. This provides a robust, state-backed funding avenue for civilian MedTech solutions that possess potential military applications, known as dual-use technology. Such technologies cover a wide range of cutting-edge fields, including AI, advanced materials, biotechnologies, and cybersecurity tools. EU Funding Channels and Incentives Multiple EU financial mechanisms are being repurposed or enhanced to support this strategic objective. The European Defence Fund (EDF) is central, allocating over €1 billion for collaborative defence research and development in its 2025 Work Programme. The EDF provides substantial incentives: funding rates for Small and Medium-sized Enterprises (SMEs) and small mid-caps can reach up to 100% EU co-financing for eligible projects, dramatically reducing the financial risk for innovative smaller firms. The Strategic Technologies for Europe Platform (STEP) now explicitly includes defence and security technologies as a fourth strategic sector, confirming its role in directing significant EU funding towards these areas. Furthermore, the Digital Europe Programme (DEP) is mandated to facilitate the deployment and operation of "AI factories" and gigafactories specifically intended for defence-related AI models. This strategic focus indicates direct state investment in developing foundational AI capabilities that will naturally spill over into civilian healthcare applications, especially those requiring high-performance computing infrastructure. Focus Area: The Alliance for Defence Medical Countermeasures (ADMC) A dedicated, high-priority focus within the EDF is the Alliance for Defence Medical Countermeasures (ADMC). The EDF 2025 Work Programme allocates two specific grant agreements to support the ADMC. The primary goal of this Alliance is to establish a long-term, supportive, and sustainable cooperation mechanism across Europe. This mechanism is designed to amplify, connect, and strengthen EU medical research and development capabilities specifically concerning selected medical threats. Furthermore, it aims to guarantee the accessibility, availability, and eventual disposability of necessary medical countermeasures. Defence Medical Support is recognised as a specific funding category within the 2025 Work Programme, highlighting the explicit strategic commitment to this sub-sector. The availability of high-rate, non-dilutive capital through the EDF effectively acts as de-risking capital for MedTech innovation. This funding mechanism allows startups developing expensive, high-risk technologies—such as advanced diagnostic AI or complex bioelectronic devices (Electric Medicine)—to secure critical resources that commercial Venture Capital (VC) might otherwise deem too speculative. By positioning their solutions (e.g., rapid trauma diagnostics, mobile robotic surgery systems) as dual-use assets aligned with ADMC priorities and the broader societal resilience mandate, companies can leverage geopolitical urgency to accelerate technological validation and commercial readiness for civilian health applications. EU Strategic Funding Levers for Dual-Use Medtech (2026) EU Programme Strategic Focus Area Relevant Medtech Technology Funding Incentive (SMEs/Mid-Caps) Source Reference European Defence Fund (EDF) R&D for Defence Medical Countermeasures (ADMC) Trauma Care, Advanced Diagnostics, Biotechnologies Up to 100% EU co-financing for eligible projects Various Strategic Technologies for Europe Platform (STEP) Defence and Security Technologies, Societal Resilience Critical Infrastructure Protection, Disaster Response MedTech Addition as a new strategic sector, channelling EU funding Various Horizon Europe Dual-Use Civil Applications with Military Potential AI/ML Algorithms, Advanced Materials, Nanotechnology Supports civil applications with dual-use potential Various Digital Europe Programme (DEP) AI Infrastructure Deployment AI Factories, Defence-related AI Models/Applications Facilitates deployment of AI infrastructure Various Mega Trend 5: Dynamic Data Consent Models — EHDS and the Future of Secondary Data Use GDPR Foundation: The Need for Granular Control The current framework for utilizing health data in Europe is characterized by the fragmented application of the General Data Protection Regulation (GDPR). This fragmentation, often exacerbated by a lack of clarity regarding how obligations are met by health tool providers and professionals, has historically hampered large-scale, cross-border data sharing necessary for clinical research and digital health services. Dynamic Consent (DC) models emerged as a necessary technological and ethical solution to address these constraints. DC enhances the data subject's rights by providing granular, real-time control over how their data is shared and used, especially for research purposes. By empowering participants with continuous control, DC models increase transparency and strengthen trust in the research process, fulfilling key GDPR principles such as transparency (Article 5), data subject rights (Articles 12-22), and accountability. Several organisations, such as the RUDY Study in the UK, already utilise DC to enable participants to update their preferences continuously. The EHDS Application (March 2026): From Consent to Mandatory Sharing The application of the European Health Data Space (EHDS) regulation, commencing March 26, 2026, fundamentally alters the legal basis for secondary data use. The EHDS creates a statutory legal obligation for data holders to share electronic health data—including genetic, EHR, and healthcare-related administrative data—for defined secondary purposes, such as research, innovation, and policy-making. This transition shifts the core governance model from one requiring explicit consent for every use case to one based on mandatory sharing, managed by the new Health Data Access Bodies (HDABs). In this new environment, the role of dynamic consent evolves from being the primary legal basis for data processing to becoming the essential mechanism for managing patient autonomy and control. Dynamic Consent Management Systems (DCMS) are vital for ensuring that patients are appropriately informed about data use and, critically, for facilitating the patient’s right to exercise the legal opt-out mechanism specified by the EHDS. Furthermore, the expansion of the European Electronic Health Record Exchange Format (EEHREF) by 2026 to include complex data like imaging and lab results increases the need for robust, secure consent mechanisms. This regulatory shift creates immediate and highly regulated revenue pools specifically targeting providers of secure identity and consent-management solutions that facilitate this complex cross-border data flow. Operational Challenges: Standardisation (FHIR/OMOP) and HDAB Function Operationalizing the EHDS requires overcoming significant technical challenges, particularly in data standardization. Alignment with the EHDS framework mandates three categories of standardization: data discoverability (via Data Catalog Vocabulary Application Profile, or HealthDCAT-AP), semantic interoperability (via the Observational Medical Outcomes Partnership, or OMOP, Common Data Model), and health data exchange (via DICOM and FHIR). Proper mapping between standards (e.g., FHIR/OMOP) and the necessary extensions to OMOP to represent patient-generated health data (PGHD) remain ongoing challenges in 2026. The newly operationalised Health Data Access Bodies (HDABs) will serve as the gatekeepers, responsible for granting data permits for secondary use. Innovators must structure their data request processes—encompassing data discovery, application submission, and analysis within secure processing environments—to efficiently interface with these national bodies. Given that the EHDS shifts the legal model toward mandatory data sharing, robust implementation of Dynamic Consent Management Systems (DCMS) is not just a compliance activity, but a necessary measure of strategic risk mitigation. Transparent and easily accessible DCMS implementation is crucial for managing potential public resistance and preventing political backlash that could force governments to impose more restrictive national opt-in or exclusion frameworks. Companies that establish themselves as leaders in data transparency and patient control will become the preferred partners for both HDABs and key patient advocacy organizations, ensuring continued access to essential European health data pools. EHDS Key Requirements and Operational Impact (Post-March 2026) EHDS Component Status/Deadline (March 26, 2026) Impact on HealthTech Innovators Standardisation Requirement Source Reference Regulation Application Full application begins Mandates legal obligation to share data for secondary purposes N/A Various Data Access Gatekeeper Health Data Access Bodies (HDABs) operationalized Innovators must apply for Data Permits and adhere to HDAB rules Secure Processing Environment (SPE) Various Patient Control Mechanism Opt-out mechanism implemented (must be informed) Requires implementation of transparent patient information and consent/preference management (DCMS) N/A Various Data Interoperability Required for Discoverability and Exchange Native output must be standardized for seamless HDAB submission OMOP, FHIR, HealthDCAT-AP (under refinement) Various Synthesis and Strategic Recommendations (2026-2028) Trend Intersections and Synergies The five predicted mega trends are not isolated developments but rather facets of a unified shift toward a digitally governed, data-centric healthcare ecosystem. Convergence of Data and AI: Ambient Clinical Intelligence (Trend 3) serves as the primary mechanism for transforming previously unstructured clinical narratives (up to 80% of medical data) into standardised, high-quality, structured data. This newly generated data, if compliant with OMOP/FHIR standards, immediately becomes accessible for secondary use under the EHDS pipeline (Trend 5). This accelerated flow of clean, contextualized data is essential for training the next generation of predictive models and diagnostic algorithms required by Electric Medicine (Trend 1) and Defence Medtech (Trend 4), effectively closing the clinical innovation loop. Defence R&D Funding Civil Innovation: The geopolitical imperative driving Defence Medtech (Trend 4) provides vital, non-dilutive capital (up to 100% co-financing via EDF). This capital can be strategically leveraged to de-risk high-cost, cutting-edge technologies like graphene BCIs or complex AI-based surgical robotics within the Electric Medicine sector (Trend 1), particularly when framed as a societal resilience asset aligned with ADMC priorities. This financial bridge is essential for European competitiveness in fields where private VC funding may be overly conservative. Investment Prioritisation Matrix and Risk Mapping Strategic positioning for 2026 demands a dual approach to investment, targeting both mandated regulatory infrastructure and high-growth, validated technology. Strategy A: Regulatory Infrastructure Plays (EHDS Enablers): Institutional capital should prioritize investment in technologies that address the mandatory requirements of the March 2026 application of EHDS. This includes Dynamic Consent Management Systems (DCMS), interoperability platforms, and specialized consulting firms capable of FHIR/OMOP conversion. These areas represent low-risk, compliance-driven revenue streams guaranteed by the new legal mandate. Strategy B: High-Growth, Clinically Validated AI: Target ACI vendors and Electric Medicine innovators, such as those developing PFA competitors, that have demonstrated viable pathways for compliance with the EU AI Act and possess scalable cloud deployment capabilities. The focus should remain on companies that can prove clear clinical outcomes and maintain capital efficiency. Strategic Risk Mapping: Regulatory Compliance vs. Scale-Up (2026) Risk Area Manifestation in 2026 Impact on Scale-Up Mitigation Strategy Regulatory Overburden Concurrent requirements (MDR/IVDR, AI Act, GDPR/EHDS) Increased Time-to-Market, higher costs for SMEs; M&A acceleration Strategic partnerships with large incumbents (e.g., Philips, Microsoft) for compliance infrastructure Data Governance & Privacy Fragmented GDPR interpretation being replaced by EHDS data access requirements Risk of litigation/fines if Dynamic Consent or opt-out mechanisms are flawed Invest in specialized DCMS and HDAB-compatible interoperability layers (OMOP/FHIR) AI Validation Requirements for high-risk system transparency and data quality (AI Act, March 2026) Delay in ACI deployment without clear clinical validation and governance Leverage regulatory sandboxes (TEF-Health) and focus on systems with auditability ("Linked Evidence") Investment Volatility Investor focus shifting to capital efficiency and proven clinical outcomes Reduced funding for early-stage ventures without clear regulatory strategy Target non-dilutive R&D funding via EDF/ADMC for dual-use R&D Strategic Recommendations (2026-2028) Mandate FHIR/OMOP Alignment: Organisations should require that all new digital product development—including ACI outputs, Sleeptech data streams, and data interfaces—prioritise native FHIR/OMOP output. This pre-emptive alignment is necessary for immediate integration into the EHDS secondary data framework, ensuring competitive access to research and policy-making data flows. Establish Dual-Use Task Force: Corporations and specialised MedTech SMEs should create a dedicated task force to proactively identify dual-use technology opportunities and aggressively pursue EDF and STEP funding. Focusing on the Alliance for Defence Medical Countermeasures is a high-return strategy to offset civilian R&D costs and secure essential late-stage validation capital. Invest in Trust Infrastructure: Dynamic Consent Models should be viewed not as a compliance cost centre, but as a critical trust differentiator. Robust, transparent DCMS implementation is necessary to secure public acceptance and utilization of EHDS, safeguarding against political interference that could mandate more restrictive national data frameworks, thereby ensuring long-term access to essential data pools. Prioritise Compliant Cloud-Native Deployment: Executives must accelerate hospital and health system readiness for compliant cloud adoption (e.g., Azure or AWS infrastructure). This is crucial for unblocking the inevitable surge in demand for high-processing-power AI applications, such as ACI, which require scalable, secure, and compliant cloud environments to function effectively within the parameters of the AI Act and GDPR. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Ambient Clinical Intelligence powered by Ambient Voice Technology: Top Funded StartUps and ScaleUps in the USA and Europe Executive Summary: The Financialisation of Clinical Documentation The Ambient Clinical Intelligence (ACI) sector, powered by Ambient Voice Technology (AVT), has transitioned rapidly from a nascent concept to a primary focus for large-scale venture capital deployment within enterprise healthcare. The underlying technology, rooted in Generative AI (GenAI), is fundamentally disrupting clinical workflows, promising to alleviate the persistent crisis of physician burnout driven by administrative documentation burden. Synthesis of Findings and Key Investment Statistics The market dynamics are characterized by unprecedented speed and scale in capital infusion, confirming ACI as the foremost application of GenAI in health systems. The analysis reveals a stark financial hierarchy dominated by two hyper-funded organisations: Abridge Inc. and Ambience Healthcare. These companies collectively command well over $1 Billion in total funding raised through mid-2025. This rapid and massive investment confirms that ACI is no longer viewed as a marginal tool but as a "must-have" utility for large integrated health systems. The pace of growth is best exemplified by Abridge, which secured a remarkable $300 Million Series E round in June 2025, elevating its valuation to $5.3 Billion. This exponential increase in valuation and funding velocity signals profound investor confidence in the organisation's ability to not only capture significant market share but also to integrate deeply into core clinical and revenue cycle management (RCM) workflows. The strategic imperative driving this financial momentum is the market's shift beyond simple AI-powered dictation towards Agentic AI. This advanced capability allows systems to handle complex, end-to-end tasks, including automated documentation, proactive coding suggestions, revenue cycle functions, and compliance assurance. Organisations that can prove high reliability and utility across the entire clinical and financial spectrum are attracting the largest valuations. Top 10 Ranking Snapshot By Total Capital Raised The following table summarises the financial hierarchy within the ACI sector, based on available funding disclosures through 2024 and 2025. Rank Company Est. Total Funding (USD) Latest Funding Round Valuation (Est.) Key Investors & Status 1 Abridge Inc. $773M - $800M Series E ($300M, Jun 2025) $5.3 Billion Andreessen Horowitz (a16z), Khosla Ventures 2 Ambience Healthcare $313M Series C ($243M, Jul 2025) $1 Billion OpenAI Startup Fund, Kleiner Perkins, Oak HC/FT 3 Suki AI $165M Series D ($70M, Oct 2024) ∼283M (Series D Post-Money) N/A (VC backed) 4 Augmedix $158.5M Various (Pre-acquisition, 2023) Acquired ($$$139M, 2024) HCA Healthcare, Redmile Group (Exit Benchmark) 5 Nabla $120M Series C ($70M, Recent) N/A HV Capital, Highland Europe 6 Heidi Health ∼100M Series B ($65M, Recent) $465 Million Point72 Private Investments 7 DeepScribe $60M Series A ($30M, Jan 2022) N/A Index Ventures 8 Tandem Health $59.5M Series A ($50M, Jun 2025) N/A Kinnevik, Northzone, OpenAI 9 Freed AI $34M Series A ($30M, Mar 2025) N/A Sequoia Capital, Scale Venture Partners 10 Emerging Pipeline <$30M N/A N/A N/A The Foundational Shift: Ambient Voice Technology (AVT) and Generative AI in Healthcare Ambient Voice Technology, operating under the broader framework of Ambient Clinical Intelligence (ACI), represents a paradigm change in how technology interacts with clinical practice. This shift is essential to understanding why capital is flowing into the sector at such high volumes. Defining Ambient Clinical Intelligence (ACI) ACI is a realisation of "pervasive infusion of AI that is seamlessly embedded into the ways we live and work," moving away from previous technological solutions that required clinicians to actively inject data into systems. In healthcare, ACI is fundamentally the driving force aimed at restoring the core satisfaction of medical practice and improving patient engagement. These AVT solutions, commonly termed "ambient scribes," utilise automated speech recognition (ASR) combined with sophisticated large language models (LLMs) to passively "listen" to clinical consultations. Their core function is to convert the natural, free-flowing audio interaction between a patient and a physician into structured, clinical documentation, often generating a draft of the medical note. The transformative goal is explicitly to remove the cognitive burden associated with concurrent or post-visit Electronic Health Record (EHR) data entry, allowing physicians to be more present and conversational with patients. Technological Drivers and the LLM Convergence The convergence of technological innovations, particularly in mobile devices, the Internet of Things (IoT), and advanced computing power, set the stage for ACI adoption. However, Generative AI (GenAI) is the primary catalyst. ACI solutions represent the first large-scale application of GenAI within health systems, leading to adoption speeds significantly faster than historically observed in the notoriously slow-moving health IT industry. Specialised ambient GenAI tools, such as Nuance DAX, Speke, and Tandem Health, leverage LLMs to process the conversational audio. The capability of LLMs to summarize complex clinical data and generate tailored, structured responses in various documentation styles is paramount to alleviating documentation pressure. While GenAI offers immense utility, its power introduces significant challenges. Reliance on LLMs carries inherent risks concerning the quality of source data, which may introduce systemic biases, or the generation of entirely false information, known as "hallucinations". Addressing this critical safety challenge is becoming a primary differentiator. Suki AI, for instance, explicitly mitigates this risk by focusing on "Evidence-linked documentation" designed to reduce hallucinations and bias, ensuring content is clinician-reviewed before integration into the EHR. This emphasis on clinical safety and reliability is a necessary feature for achieving widespread, trusted adoption among large, risk-averse health systems. Quantifying the Value Proposition: Operational and Human Impact The aggressive funding environment is directly tied to the quantifiable, significant return on investment (ROI) that ACI solutions deliver, particularly in addressing the physician burnout crisis. Reported outcomes demonstrate substantial improvements in the clinical environment. Clinicians using ACI solutions report a 70% improvement in work-life balance and an 80% reduction in cognitive burden and fatigue. These human benefits translate directly into crucial efficiency gains. On average, physicians save 5 minutes per patient encounter, accumulating to substantial recovered time throughout a clinic day. Furthermore, the non-clinical value is equally compelling: 93% of patients surveyed indicate that their physician is "more personable and conversational" when using the technology, proving that ACI successfully shifts the clinician's focus back to the patient rather than the computer screen. The speed of ACI adoption, accelerating faster than nearly any other recent technology deployment in healthcare, suggests that health system leadership views the administrative burden and resulting clinician burnout as an immediate, existential crisis. The necessity for rapid deployment of solutions that guarantee a high return in human capital retention, as demonstrated by the 70% work-life improvement, is fuelling the competitive drive for large funding rounds. Consequently, the competitive edge is shifting away from merely accurate automatic speech recognition (ASR) to ensuring full regulatory compliance, auditability, and deep EHR integration. The risk associated with Generative AI (hallucinations) requires high engineering standards, making features like Suki’s evidence-linked documentation critical for enterprise adoption that secures the competitive advantage. The ACI Funding Landscape: Tracking the Digital Health Mega-Rounds The capital influx into ACI must be viewed within the context of the broader, resilient digital health venture capital ecosystem of 2024 and 2025. 2024-2025 Digital Health VC Trends Despite global economic volatility, the digital health sector has shown resilience. Funding in 2025 reached $9.9 Billion through the third quarter, surpassing the $8.4 billion raised during the same period in 2024. This robust activity is largely attributable to the phenomenon of "mega-rounds" (deals worth $100 million or more). These mega-deals accounted for approximately 40% of the total digital health investment in 2025, reaching $3.8 billion. Abridge and Ambience are prime examples of this trend, successfully securing enormous financing to rapidly scale. Investment prioritisation is clearly concentrated in technology categories that automate core processes using AI. The top three funded value propositions—non-clinical workflow, clinical workflow (both raising $1.9 billion), and data infrastructure ($893 million)—account for over half of all digital health funding. ACI solutions, which span both clinical and non-clinical documentation, sit at the intersection of these two most lucrative investment categories. The Established Incumbent: Nuance Communications (Microsoft) While the focus of this analysis is on emerging venture-backed scaleups, Nuance Communications, now a part of Microsoft, sets the crucial benchmark for market maturity and enterprise readiness. Nuance DAX utilizes specialized GenAI tools to "listen" to consultations and generate notes. Nuance, founded in 1992, is an established enterprise software provider, operating as a public company with estimated revenue of $1.25 Billion prior to its acquisition. Its status validates the overall market demand but also establishes a high competitive floor, particularly regarding product maturity and integration depth. Nuance DAX is widely known for its "Deep Epic" and Meditech integration capabilities, setting the necessary standard for any scaleup seeking major health system contracts. The existence of Nuance, and its acquisition by a technology giant, signals to investors that high-value, market-dominant exit opportunities are achievable in the ACI space. This validation was reinforced by the acquisition of Augmedix, which had raised $158.5 million before being bought by Commure for $139 million in 2024. This transaction provided a tangible, high-profile exit precedent, validating the investment thesis that successful ACI companies—even if not reaching IPO scale, are desirable targets for established health IT vendors seeking to quickly acquire GenAI capabilities and an installed user base. The Thesis Behind Scale: Capitalising on Integration and Compute The massive capital accumulation by Abridge and Ambience is not simply for marketing; it is essential for enterprise scaling. These large Series C and E rounds fund several high-cost necessities: securing complex enterprise contracts, navigating notoriously long sales and implementation cycles, and, most critically, continuous investment in proprietary, specialised LLMs optimised for nuanced medical language and specific documentation styles. The ACI funding competition is fundamentally a strategic acquisition race for deep, functional EHR integration. Leading firms like Suki emphasize their "Deepest integration with EHRs," specifically naming major enterprise platforms such as Epic, Oracle Health, and MEDITECH. The enormous funding rounds secured by the top-tier players are intrinsically linked to the high engineering and compliance costs associated with securing reliable, deep integration needed to deploy across major health systems. This technical achievement creates a powerful competitive moat, significantly outweighing the core AI model itself in enterprise decision-making. Abridge's soaring valuation of $5.3 Billion suggests investors are applying a substantial revenue multiple, betting that the company can rapidly evolve its technology from a simple documentation tool into an indispensable layer of the health system's operating infrastructure. This valuation is based on the expectation that deep EHR integration and expanded capabilities, such as revenue cycle intelligence—will ensure long-term, utility-level market capture. Deep Dive: Top 10 Most Funded Ambient Voice Technology Startups/Scaleups This section profiles the leading AVT scaleups, detailing their financial profiles and strategic differentiation, based on the total capital raised. A. Tier-1 Leaders: The Platform Builders ($>300M Raised) Abridge Inc. (The Velocity Leader) Abridge has demonstrated unmatched financial velocity in the sector, raising approximately $773 million to $800 million in total funding. The company's rapid acceleration culminated in a $300 million Series E round in June 2025, led by Andreessen Horowitz and Khosla Ventures, pushing its valuation to a reported $5.3 billion. The timeline is significant: this Series E closed just four months after its prior Series D round. Abridge positions itself as a provider of an AI-based health record platform that converts natural conversation into a structured clinical note draft in real time, leveraging a proprietary data set derived from over 1.5 million medical encounters. Its current strategic focus is expansion, including support for inpatient notes and orders within Epic, and the crucial plan to embed revenue cycle intelligence earlier into the clinical conversation. Ambience Healthcare (The Full-Cycle Agent) Ambience Healthcare has secured its status as a market unicorn, raising $313 million in total funding. This total is anchored by an enormous $243 million Series C round in July 2025, which immediately granted the company a $1 Billion valuation. Its investor base includes notable names such as Kleiner Perkins, Oak HC/FT, and, significantly, the OpenAI Startup Fund. Ambience markets its product as a comprehensive, connected system that supports the entire clinical workflow: pre-visit, during-visit (Ambient Scribe), and post-visit. Its core strategic differentiation lies in its Post-Visit suite, which applies coding logic and compliance intelligence to generate "audit-ready, revenue-optimized documentation". This focus on end-to-end compliance and revenue capture allows Ambience to position its offering as a revenue integrity tool, going beyond simple time savings. Tier-2 Scaleups: The Differentiated Players ($100M - $300M) Suki AI (The Integration Standard) Suki has raised a total of $165 million, following a $70 million Series D funding round announced in October 2024. This round placed its post-money valuation at approximately $283 million. Suki’s primary strategic emphasis is on the robustness of its platform and superior EHR integration capabilities. The company explicitly claims to set the "standard for what's possible for EHR integrations," highlighting full integration with major enterprise systems including Epic, Oracle Health, athenahealth, and MEDITECH. Suki’s platform is designed as a "true assistant," encompassing ambient documentation, dictation, ICD-10 and HCC coding, order staging, patient summaries, and Q&A. The incorporation of evidence-linked documentation also serves as a critical clinical safety measure against LLM hallucinations. Augmedix (The Exit Benchmark) Augmedix raised $158.5 million across multiple funding rounds leading up to its acquisition. Before the exit, the company also executed a NASDAQ uplift offering in 2021. Augmedix was acquired by Commure for $139 million in 2024. Augmedix represents the first generation of successful digital scribing solutions, often utilizing a hybrid AI/human approach. Its acquisition serves a crucial function in the ecosystem: providing a high-profile M&A valuation marker for the ACI sector, confirming the investment thesis regarding viable exits for companies achieving significant scale and adoption. Nabla (The Agentic Pioneer) Nabla has raised a total of $120 million, boosted by a recent $70 million Series C round. The company is trusted by over 130 healthcare organizations and 85,000 clinicians. Nabla's strategic focus is on evolving beyond a mere documentation tool into an adaptive, "Agentic AI" platform. Agentic AI is designed to go deeper into clinical workflows by supporting advanced coding tasks, generating agentic EHR commands, and assisting a wider range of clinical roles. This specialsation is key to delivering measurable ROI across complex clinical and financial processes. C. Fast Followers and Regional Contenders ( $<$100M) The market reveals a clear bifurcation in funding strategy. While Abridge and Ambience utilize hyper-funding to dominate the complex US enterprise EHR market, other well-funded scaleups focus on geographical advantages and specialised niches. The fact that the OpenAI Startup Fund is listed as an investor in both Ambience Healthcare and the European scaleup Tandem Health suggests a strategic technical alignment, potentially granting these firms a deep technological advantage through preferential access to or collaboration on foundational models. Heidi Health: This Australian-based company has raised approximately $100 million in total funding, securing a $65 million Series B round, valuing the company at $465 million. Its strategic ambition is international expansion, focusing on challenging, fragmented markets across the USA, UK, Canada, France, and other global regions. DeepScribe: The company has raised $60 million, driven by a $30 million Series A round in January 2022. DeepScribe competes by offering robust scribe software with necessary EHR compatibility. Tandem Health: Based in Stockholm, Tandem Health is leading the European market charge. It recently raised a significant $50 million Series A round in June 2025, bringing its total funding to $59.5 million. Its early success includes rapid deployment across Europe, including a partnership with Accurx in the UK, reaching over 200,000 NHS professionals. This scaling demonstrates a high-potential, specialized acquisition path for vendors focusing on complex, non-US health systems. Freed AI: Freed recently secured a $30 million Series A round in March 2025 (total funding $34 million), backed by Sequoia Capital. The company focuses on delivering instant clinical documentation for thousands of clinicians. Competitive Dynamics and Strategic Positioning The competitive battleground in ACI is defined by two primary dynamics: achieving non-negotiable EHR interoperability and migrating from simple dictation functionality to complex, revenue-driving Agentic AI. The Interoperability Barrier: EHR Integration as a Core Asset For top-funded ACI firms, deep and reliable integration with dominant EHR platforms—primarily Epic, Oracle Health, and MEDITECH, is the minimum entry requirement for securing large-scale health system contracts. Suki's explicit claim of setting the standard for broad, certified EHR integrations underscores the market's emphasis on platform robustness over core AI novelty. This integration is complex because it must ensure documentation is not only accurate but also correctly structured and compliant with the EHR’s native documentation standards. Failure in this area leads directly to required manual rework, which clinicians cite as a major barrier to adoption. The high capital deployed by Tier-1 companies is necessary to acquire the engineering talent and proprietary datasets to achieve this seamless, non-disruptive interoperability, which is far more critical for enterprise sales than basic functionality. B. Product Differentiation: From Scribe to Agentic AI and RCM Integration The current funding landscape reflects a consensus that simple documentation is insufficient; the next generation of ACI must address the financial integrity of the clinical encounter. The Evolution to Agentic Workflow: Leading firms are rapidly moving away from simple AI scribing toward providing complex, multi-step assistance, defining their offerings as Agentic AI. This shift involves the AI initiating and completing clinical and administrative actions based on conversational input, rather than merely producing a draft. Focus on Revenue Cycle Management (RCM): A key strategic differentiator is the integration of RCM logic directly into the clinical documentation process. Ambience Healthcare is a pioneer in this area, utilising its Post-Visit suite to apply "coding logic, compliance intelligence" to generate "revenue-optimised documentation" that produces "cleaner claims from the start". Abridge has also identified RCM integration as a future expansion point. By linking documentation directly to financial outcomes, these firms elevate their status from a discretionary expense to an indispensable financial utility layer. This focus on compliance and financial integrity explains why enterprise health systems are willing to pay premium prices for solutions offered by the top-funded players (e.g., Nuance DAX at up to $830/mo, Suki at $299/mo) , rather than adopting low-cost alternatives. The high price is justified by the promise of improved revenue integrity, decreased risk of audits and queries, and reliability that minimises the chance of manual rework for already overburdened clinicians. The competitive edge is thus determined by the ability to generate a clinical note draft that is not only accurate but audit-ready and compliant, requiring near-zero correction. Governing the Future: Ethical, Regulatory, and Clinical Challenges For ACI technology to achieve widespread deployment across risk-averse health systems, the massive capital investment must be paired with rigorous oversight addressing inherent ethical, regulatory, and safety risks. Privacy and Data Governance: The Continuous Monitoring Dilemma Ambient intelligence requires the continuous collection of substantial amounts of audio and sensor data in patient care settings. This presents immediate ethical challenges concerning privacy, data management, potential bias, and informed consent. The deployment of these systems forces health systems to navigate complex legal risks. Existing state laws regarding consent for audio recordings were not designed for continuous, ambient AI monitoring, leading to ambiguity in implementation. Compliance is crucial, but health systems must also provide transparency regarding the AI's use to maintain public trust and provide patients the opportunity to make informed decisions about their personal information.Regulatory frameworks are playing catch-up, and careless implementation of ACI may introduce novel legal risk profiles if compliance and auditability are not strictly managed through the platform. The Accuracy Mandate and Clinical Safety The use of Large Language Models introduces unique clinical safety risks that must be mitigated by top-tier ACI providers. A major concern is the possibility of LLMs introducing outright false information, or "hallucinations," or skewed recommendations resulting from inherent bias in the training data. The conversational nature of the AI output can make users susceptible to misinformation, posing risks to patient safety. The scale of funding directly correlates to the ability of a company to achieve clinical accuracy. Abridge’s claim of deriving its technology from over 1.5 million medical encounters and supporting 55 specialties is evidence that the massive capital raises are essential for acquiring and processing the proprietary training data required to specialize the LLMs. This huge, specialized data volume is necessary to minimize generalization errors and hallucinations, which, in turn, builds clinical trust and reduces the burdensome need for manual corrections. Rigorous oversight and careful implementation are necessary to ensure accuracy, ethical integrity, and alignment with established clinical standards. Adoption Roadblocks and Change Management Beyond technology and compliance, clinician adoption remains a critical practical hurdle. Resistance to adopting ambient voice technology often stems from a fear of disrupting established practices and specific anxieties regarding the technology itself. Major barriers include: Privacy Apprehension: Clinicians are often concerned about potential patient privacy breaches associated with constant audio monitoring. Accuracy and Rework: Doubts about the AI’s accuracy create the fear of subsequent manual rework, which negates the time-saving benefit. Training Burden: The challenge of allocating valuable clinic time for training and ensuring ongoing technical support remains a practical operational concern. Successful deployment requires health systems to manage this change by proving that the AI's documentation is indeed audit-ready and requires minimal correction, thereby ensuring high clinician engagement and trust. Outlook and Strategic Recommendations The ACI market is defined by a high-stakes, hyper-capitalized race to capture the enterprise utility layer of clinical workflow. The future trajectory suggests rapid consolidation and the increasing necessity for deep strategic partnerships. Market Growth Projections (2026-2030) The high funding velocity of Abridge and Ambience signals that market consolidation is imminent. These leaders possess the capital reserves necessary to acquire smaller, specialized competitors that hold niche RCM expertise or strong regional deployment advantages (such as Tandem Health in Europe). A key factor to watch is the response of incumbent EHR giants. To prevent rivals from gaining platform-level dominance through deep integration, EHR vendors will likely accelerate M&A activities, seeking to integrate ACI capabilities natively or secure exclusive partnerships with the leading scaleups. Recommendations for Health Systems (Adoption Criteria) For health system Chief Strategy Officers and Chief Information Officers, strategic ACI adoption must adhere to criteria that extend beyond superficial convenience: Prioritise Agentic Capabilities and RCM Integration: Solutions must demonstrate measurable financial ROI by extending utility beyond simple documentation to proactively supporting coding, compliance, and core revenue cycle functions. Choosing a system based solely on time saved, without verifying RCM benefit, presents a suboptimal investment. Demand Proven Interoperability Depth: Rigorous due diligence is mandatory regarding the depth and reliability of integration with core EHR systems (Epic, Oracle Health, etc.). Compatibility is insufficient; the system must demonstrate high-speed, compliant, and rework-free integration. Establish Robust Data Governance: Clear, auditable protocols for informed consent, data privacy, and continuous audio capture must be developed and strictly enforced. Mitigation strategies for LLM risks (hallucinations, bias) should be central to the vendor selection process to manage ethical and legal risk. Recommendations for Investors (Risk/Reward Analysis) For venture capital funds evaluating the ACI landscape, strategic guidance should focus on long-term technological moats and verifiable utility: Focus on the Utility Layer: The investment thesis should favor companies that can prove their transition from a documentation feature to a non-discretionary utility layer, deeply embedded in the health system’s RCM and clinical command structures (e.g., Abridge and Ambience). Monitor Geopolitical Niches: Significant opportunities exist in fast-scaling players that successfully navigate complex, highly regulated non-U.S. markets (e.g., Tandem Health’s NHS focus). These firms present high-value, specialised acquisition targets for major health tech platforms seeking global expansion. Evaluate Technical Moats Beyond Funding: Capital alone is not the sole differentiator. Investors must rigorously assess the true technological moat, specifically focusing on proprietary LLM training data derived from vast, specialised encounter volumes and strategic technical alignment, such as partnerships with foundational AI providers (like OpenAI, as noted with Ambience and Tandem). Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors featured in Forbes: 5 High-Growth Business Models Set To Thrive In The Coming Decade Nelson Advisors thought leadership has been referenced in the Forbes article '5 High-Growth Business Models Set To Thrive In The Coming Decade' outlining five business models that are primed for success in the coming years. 5. HealthTech and Telemedicine The intersection of healthcare and technology is one of the most promising areas for growth over the next decade. HealthTech innovations such as telemedicine platforms, AI-driven diagnostics, and wearable health devices, are revolutionizing how healthcare is delivered and accessed. With the global population aging and the demand for healthcare services increasing, the need for efficient, accessible, and personalized healthcare solutions is critical. Telemedicine experienced a surge in use during the pandemic and is expected to remain a cornerstone of healthcare in the future. Startups that focus on improving patient care through technology such as remote monitoring or mental health apps will be well-positioned for growth. The bottom line is that the next decade promises to be an exciting time for entrepreneurs willing to tap into these business models. Whether it's leveraging technology to personalize customer experiences, prioritizing sustainability, or creating innovative solutions for remote work and healthcare, the opportunities for growth are vast. By staying ahead of these trends and adapting your business model accordingly, you can position yourself for long-term success in a changing market. Source: https://www.forbes.com/sites/melissahouston/2024/10/15/5-high-growth-business-models-set-to-thrive-in-the-coming-decade/ Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Defence MedTech: New market emerging combining defence innovation and medical technology Executive Summary: The Strategic Imperative of Defence MedTech Convergence Summary of Findings and The Investment Thesis The intersection between defence innovation and medical technology (MedTech) represents a fundamental structural shift, moving beyond simple technological spillovers to establish a mutually reinforcing economic and R&D ecosystem. Military Research and Development (R&D) functions as a highly accelerated, high-stakes validation engine, forcing the creation of exceptionally robust, autonomous, and efficient medical capabilities required for assured care in austere and contested environments. The essential investment thesis rests on the unique value proposition generated by this convergence. Technologies perfected under extreme military constraints, such as advanced trauma care, battlefield robotics, and real-time physiological monitoring, are inherently de-risked and optimised for portability and reliability, fulfilling critical unmet needs in the broader global civilian healthcare sector, including disaster response, rural access, and mass casualty management. To capitalise on this opportunity, firms must adopt a sophisticated dual use strategy,, defining clear priorities and trade-offs to successfully build products simultaneously for both commercial and military customer bases. The Market Opportunity and Principal Strategic Risks The overall MedTech market exhibits predictable, stable growth, providing a robust foundation for investment. Global market size estimates range from USD 668.2 billion to USD 681.57 billion in 2025, with projected Compound Annual Growth Rates (CAGR) generally falling between 4.4% and 7.0% through 2030, driven by innovation and infrastructure investment. However, Defence MedTech directly targets the high-growth frontier sectors. The transition from hospital-based to home-based care and the adoption of AI-powered solutions are major tailwinds accelerating MedTech growth. Specifically, the total addressable market (TAM) for Digital Health Ecosystems, fueled by AI, remote patient monitoring (RPM), and data integration platforms, is estimated to reach $140 billion by 2025, with projections for double-digit CAGR. Defence-originated technology holds a significant advantage in capturing this value due to its mandate for rugged, secure, and remote functionality. The primary strategic risks to this convergence are systemic and governance-related. First, the successful transition (T2) from defence use to commercial markets is impeded by systemic regulatory friction, particularly regarding the navigation of FDA pathways for Military Priority Products (MPPs) and the transfer of regulatory clearances like 510(k)s.Second, the rapid advancement of military Artificial Intelligence (AI) introduces profound ethical and legal complexities stemming from the dual-use nature of the technology, where life-saving systems risk being repurposed for lethal applications (Lethal Autonomous Weapons Systems, or LAWS). The Dual-Use Paradigm: Architecting the Defence Civilian Nexus Defining the Dual-Use Technology Framework and Strategic Orientation The concept of dual-use technology extends beyond specific end products to encompass goods, software, and underlying technologies that possess both civilian applications and potential military or terrorism use. The U.S. Department of Defense (DoD) recognizes dual-use products such as aircraft engines, global positioning systems (GPS) used for navigation, and most medical and safety equipment used by the DoD. Furthermore, dual-use applies to fundamental manufacturing processes, including computer-aided design (CAD), soldering, and process control, which are often tied to stringent military standards. For companies operating in this space, success hinges on adopting a comprehensive Dual Use Strategy. This is not merely a classification but a detailed business plan that addresses priorities, choices, and necessary trade-offs regarding funding, testing protocols, and product architecture. This strategy must enable companies to concurrently build products for both commercial and military customer bases while navigating distinct market challenges, such as specialised military procurement regulations and standard commercial contract teams. The complexity of distinguishing between offensive and defensive solutions, particularly as technological lines blur, necessitates continuous scrutiny. Investment funds, such as those governed by the European Investment Fund, increasingly accept dual-use investments provided they explicitly exclude weapons and ammunition. The evolving nature of technological convergence means that a company’s long-term viability is determined less by the initial technological capability and more by its capacity to manage the associated risks across international regulatory frameworks, such as the Export Administration Regulations (EAR). The sophisticated corporate governance required to mitigate export control risk, ensure compliance, and maintain brand viability in both spheres should be viewed by investors as a tangible governance premium for these complex organisations. The Historical Precedent: Military Medicine as a Catalyst for Modern Healthcare Historically, military medical requirements have served as a crucible for medical advancement, often forcing paradigm shifts that accelerate progress and universally benefit civilisation. This dynamic has resulted in countless innovations that are often taken for granted in contemporary civilian settings. Early examples illustrate military medicine's foundational contribution. In the early 1800s, Surgeon General Joseph Lovell pioneered studies connecting weather patterns and disease. A crucial public health breakthrough occurred in 1900 when Major Walter Reed headed the Yellow Fever Commission in Cuba, successfully discovering that mosquitoes carried the disease, saving countless lives globally. Similarly, the engineering and aerospace medicine fields benefited from military research, such as Major General Harry George Armstrong and Dr. John Heim building a centrifuge in 1935 to test human reaction to acceleration, thereby improving conditions for pilots. This commitment to rigorous, data-driven methodology continued, exemplified by the establishment of the Wound Data and Munitions Effectiveness Team during the Vietnam War in 1965. This team comprised medical and weapons experts who systematically collected data on injuries sustained by service members. Their findings were subsequently used to improve the design and effectiveness of protective gear and military weapons, demonstrating an early iterative feedback loop foundational to modern trauma research. Furthermore, historical surgical collaborations, such as those involving Colonel Michael DeBakey, demonstrate that structured exchange between military and civilian surgeons has driven major innovations like damage control surgery. These examples underscore that the military R&D environment functions as a unique, non-dilutive Stage 4 Clinical Trial, forcing robustness, mobility, and efficiency that significantly de-risks a product before commercialisation. Modern Strategic Drivers: The Mandate for Assured Care Current U.S. DoD strategy emphasises medical modernisation to support joint forces operating in austere, contested environments, specifically citing the Indo-Pacific and Arctic regions. This necessitates the development of sustained, expeditionary medical capabilities far from established infrastructure. The Defense Health Program (DHP) allocates significant funding toward basic research to support this objective. Priority areas include injury prevention and recovery associated with blunt, blast, accelerative and neuro sensory injuries. Annual plans support research into innovative solutions for managing combat-related trauma, focusing on key areas such as Tactical Combat Casualty Care, Brain Trauma, Severe Burns, and Prolonged Care. Prolonged Field Care Practices involve creating protocols for extended care in resource-limited or remote settings, a critical innovation with direct civilian application in remote healthcare and disaster zones. Furthermore, research is heavily focused on optimising human performance and sustained medical readiness. This includes identifying objective biomarkers for musculoskeletal injury prevention, understanding the mechanisms of fatigue and nutrition, and researching performance degradation under extreme operational environments. Programs such as the Health Readiness and Performance System (HRAPS) are already assessing the physiological parameters of soldiers in real-time during military exercises, driving the creation of highly sensitive, mission-aligned monitoring technology. Frontier Technologies: The Engine of the Revolution Advanced Trauma, Materials and Expedient Surgery A critical area of innovation is focused on enhancing trauma care capabilities at the point of injury and throughout the evacuation chain. The Trauma Research and Combat Casualty Care Collaborative (TRC4), an initiative of The University of Texas System, collaborates closely with the DoD, having awarded $18 Million in grants to accelerate trauma research across academic institutions. Research priorities include advanced wound-healing materials designed specifically for battlefield environments. The European Defence Fund (EDF) 2025 similarly calls for funding research into advanced wound care, biodegradable bandages, and self-healing materials for use in mobile medical units and field hospitals. These comprehensive trauma initiatives extend beyond immediate field care to include programs aimed at improving long-term outcomes, such as the SWATT the FLAME burn initiative, which seeks to reduce mortality and improve metabolic recovery in severe burn patients. Expeditionary medicine also requires optimising logistics for haemorrhage control, blood products, and en route care technologies to maximise patient survival outcomes during transport. AI, Robotics, and Human-Technology Teaming The integration of Artificial Intelligence (AI), Augmented Reality (AR), and robotics is poised to fundamentally revolutionise field care by maximising system capacity and providing consistent, cognitive assistance, leading toward the “Pinnacle of Automation & Optimisation”. This vision entails human medical providers working collaboratively with robotic actors and AI in an efficient manner to manage large volumes of casualties with limited human resources. Researchers at the Johns Hopkins Applied Physics Laboratory (APL), in collaboration with the Army’s Telemedicine and Advanced Technology Research Center (TATRC), are pioneering systems for Adaptive Human-Robot Teaming. AI-based virtual assistants are being developed to give medical advice to medics and soldiers in the field, while Augmented Reality (AR) provides novel visualisations of real-time patient condition data. One crucial development is the Clinical Practice Guideline-driven AI (CPG-AI), a Large Language Model (LLM) designed to provide medical guidance to untrained soldiers in plain English, applying knowledge gleaned from established care procedures. This conversational approach is more effective in chaotic environments than traditional, structured AI. The military’s explicit focus on developing AI to coach novices reveals a powerful commercial utility: generating cognitive scaffolding for clinical practice when expert human resources are scarce. Companies investing in these LLMs are essentially developing a proprietary, medically validated, and highly reliable AI kernel. Once adapted for civilian use, this kernel offers superior performance and trustworthiness for clinical decision support systems compared to general-purpose commercial LLMs. Robotics are increasingly enabled to perform crucial, delegated tasks. In test scenarios, semi-autonomous robots are trained to fetch intubation kits, autonomously take over the ventilation (bagging) of a patient, and use specialized sensors to measure and relay vital signs from nearby casualties back to the human medic. The goal is a system with adjustable autonomy that dynamically shifts responsibilities between humans and robots based on the situation, promoting team transparency and trust through shared task knowledge. Digital Health, Monitoring and Predictive Analytics Military investment in pervasive physiological monitoring is driving the shift toward proactive, decentralized care models, mirroring the macro trend toward home-based healthcare. Defence agencies use wearable health technologies to monitor soldiers’ vital signs in real-time, tracking hydration, stress levels, and fatigue. This enables proactive medical intervention designed to optimize warfighter performance and overall readiness. Remote Patient Monitoring (RPM) has been integral to the Military Health System (MHS) for over 30 years, augmenting care for chronic conditions. During the COVID-19 pandemic, the Defense Health Agency (DHA) rapidly deployed RPM capabilities to keep providers and patients safe, optimize limited staffing, and reduce emergency room admissions. This technology is critical for extending quality medical care to military families and veterans in remote or underserved areas, directly translating to enhanced digital health services for the civilian population. Furthermore, advanced digital systems like MCPLUS (Medical Casualty Predictive Logistics Utilisation System) are being developed to leverage real-time data to anticipate medical supply needs and logistics requirements, ensuring readiness and improving operational efficiency. The Market Revolution: Commercialisation Pathways and Economic Opportunity Global MedTech Landscape Context and Opportunity Sizing The global Medical Devices Market size is projected to reach USD 681.57 Billion in 2025 and USD 955.49 Billion by 2030, representing a 6.99% CAGR. While MedTech demonstrated strong resilience throughout 2024 despite economic headwinds, the sustained growth is being driven by technological innovation, M&A activity, and the emergence of new business models. The convergence with defence aligns perfectly with several powerful macro trends, notably the increasing demand for digital health solutions (65% telemedicine adoption) and the shift away from hospital centric care. Devices developed for military operations which require robustness, portability and independence from fixed infrastructure are perfectly suited to capture value within the Digital Health Ecosystems TAM, which McKinsey estimates will reach $140 Billion by 2025, focused on high-value areas like clinical decision enablement and chronic condition management. A significant, yet often unquantified, market value is the military mandate for high reliability. Civilian MedTech currently faces concerns regarding interoperability and rising cybersecurity challenges. Military devices, however, are designed for mission-critical failure prevention in the most extreme and remote environments. This inherent military-grade reliability and embedded data security (necessary for HIPAA-compliant integration in military-civilian partnerships) is a crucial commercial asset. This proven resilience justifies premium pricing and accelerates institutional adoption in high-risk civilian clinical settings, such as emergency rooms and air ambulance transport systems. Global MedTech Market Outlook and Dual-Use Addressable Segments (2025) Market Metric Global MedTech Industry (Total) Digital Health Ecosystems (Dual-Use Relevant TAM) Significance for Defence MedTech Estimated Market Size (2025) USD 668.2 Billion to USD 681.57 Billion USD 140 Billion Targets high-growth, high-margin, software-integrated segment. Growth Rate Focus 4.4% to 7.0% CAGR (Overall MedTech) Double-Digit CAGR Defence MedTech acts as an accelerator and differentiator in the highest growth area. Key Drivers AI Innovation, M&A, Shift to Home Care, Infrastructure Investment Clinical Decision Enablement, Chronic Condition Management, Workflow Improvement Military focus on ruggedness/interoperability aligns perfectly with home care and workflow needs. Case Studies in Successful Technology Transfer and Commercial Models The history of military medicine is rich with examples of successful technology transfer (T2). One notable case is the evolution of field hemostasis control. Commercial tourniquets, such as the Combat Application Tourniquet (CAT), were originally designed for servicemen and women. Rigorous testing has demonstrated that the CAT achieves 100% arterial occlusion success across pediatric patients aged 2–16 years in controlled settings. This dual use validation has cemented commercial tourniquets as essential, life-saving tools in civilian first response for penetrating trauma and mass casualty incidents, reflecting the direct benefit of military innovation. In advanced digital technology, AI systems initially developed for military target recognition and intelligence gathering are now being applied commercially. These machine learning tools drive AI-powered imaging platforms that revolutionise diagnostic workflows, such as detecting tumors and analysing medical imaging in cardiology and neurology. To maximise commercial success, Defence MedTech companies must adopt next-generation commercial models. This involves transitioning away from traditional product sales toward providing holistic solutions by combining data and devices. Strategies include moving toward recurring revenue structures (leasing and subscriptions) and leveraging digital marketing and virtual engagement to establish closer partnerships with healthcare providers. Market Structure and Geographical Centres of Gravity Investment strategies focused on technology transfer must target established, formalised convergence ecosystems to mitigate translational risk. The United States maintains a powerful military-industrial-academic complex centered around military medicine. San Antonio, Texas, known as “Military City, USA,” is a crucial strategic nexus. The Defense Health Agency (DHA) has formalized a transformative partnership with VelocityTX, a bioscience innovation campus, positioning it as a trusted operational hub for translational science. This agreement consolidates research efforts, including those of the U.S. Army Institute of Surgical Research, under a unified, mission-aligned framework. The partnership is structured under the Federal Technology Transfer Act, ensuring robust intellectual property safeguards for all parties and requiring HIPAA-compliant integration for future research. Furthermore, academic consortia like the UT System’s TRC4 actively collaborate with the DoD, providing $18 million in grant funding to integrate advanced technologies like AI, robotics, and advanced materials into the trauma care pipeline. Globally, Israel’s Silicon Wadi holds a prestigious position as a military technology powerhouse, characterised by a deep integration of innovation between defence, academia and private tech industries. Israel is a world leader in cybersecurity and AI, with the health sector being the largest field by company count (over 1600 active companies) as of late 2023.These firms often gain accelerated access to foreign healthcare systems through initiatives like the UK Israel Tech Hub.Separately, the European Defence Fund (EDF) 2025 explicitly seeks to support medical research with broad civilian applications, focusing on areas like rapid diagnostics, antimicrobial resistance (AMR) strategies, and advanced trauma care for enhanced global public health resilience. Key Stakeholders and Their Role in Defence MedTech Transfer Stakeholder Entity Primary Role in Innovation Ecosystem Key Contribution / Focus Area Transfer/Governance Mechanism Supporting Data Points Defense Health Agency (DHA) Oversight of Military Health System (MHS) and R&D Sustaining medical readiness, Technology transfer governance (IP/HIPAA compliance) Strategic Partnerships (e.g., VelocityTX), Federal Technology Transfer Act framework Defense Advanced Research Projects Agency (DARPA) High-Risk, Transformational R&D Infectious Disease Diagnostics (DIGET), AI/Robotics, Proof-of-Concept Commercialization partners, Technology transfer (e.g., mRNA early investments) US FDA Regulatory Approval and Device Clearance Accelerated pathways for Military Priority Products (MPPs), Safety standards, 510(k) transfers MPP process, 510(k) Clearance, De Novo pathway Academic Consortia (e.g., UT TRC4) Applied Research and Clinical Trials Trauma Care, AI-powered rehabilitation, Advanced Wound Healing Collaboration Agreements with DoD, Grant funding (State/Federal) Navigating Regulatory Friction and Ethical Boundaries The Challenge of Regulatory Acceleration and Consistency The transition from military development to civilian market penetration requires navigating established and accelerated regulatory pathways, primarily managed by the US Food and Drug Administration (FDA). The DoD evaluates and prioritises Medical Priority Products (MPPs) based on the risk associated with an unmet medical need and the product’s maturity, seeking accelerated management or emergency use authorisation from the FDA. This formalised process ensures that the highest priority needs for the warfighter are addressed quickly. However, the subsequent handoff to commercial enterprises encounters significant friction. MedTech industry stakeholders have requested that the FDA provide significant clarification and consistency, particularly concerning the transfer of 510(k) clearances when a device or product line is acquired or transferred to another entity. Stakeholders demand that definitions (such as "relabeler" and "510(k) holder") be made consistent across agency guidance to prevent delays and innovation barriers, which 42% of firms report experiencing globally. This lack of consistency slows the necessary commercial handoff and inhibits broad civilian market access. Ethical Dual-Use Dilemmas of AI: The Black Box and Accountability Crisis The most significant existential risk to the scaling of advanced Defence MedTech is the unresolved ethical and legal challenge posed by AI. Technologies developed to improve diagnosis, logistics, or human performance are inherently dual-use and present a clear risk of being adapted and repurposed for lethal applications, thus enhancing autonomous weapons systems. This risk is compounded by the "black box" nature of complex AI decision making, where the output is often unexplainable, severely challenging established ethical and legal norms. In a military context, this lack of transparency complicates the assignment of accountability for the unpredictable actions of autonomous systems. Furthermore, the political and security dimensions of technology are increasingly difficult to disentangle from civilian domains, meaning the binary concept of "dual-use" often fails to clarify which applications are problematic. The lack of clarity surrounding the concept of "meaningful human control" in autonomous systems creates an accountability void in both military and civilian domains. The rapid pace of AI advancement consistently outpaces the development of governance frameworks, creating a critical regulatory and policy vacuum that risks uncontrolled deployment and ethical breaches. For dual-use AI to successfully integrate into civilian healthcare, where clinician accountability and informed patient consent are paramount, transparency is mandatory. The unpredictability of unexplainable outputs undermines patient trust and clinical utility. Therefore, the development of Explainable AI (XAI) frameworks must be viewed as a technical, regulatory, and ethical necessity. XAI not only establishes legal defensibility concerning accountability in a military context but also provides the necessary transparency for civilian regulatory approval and adoption. Future investment must be conditioned on a verifiable XAI strategy to successfully bridge the ethical and legal gap created by these powerful technologies. Data Security and Privacy Effective technology transfer requires hybrid compliance models that successfully manage the dual nature of patient data, military readiness information versus civilian health records. Partnerships between the DoD and commercial or academic partners, such as the DHA/VelocityTX agreement, are essential because they mandate HIPAA-compliant integration from the outset, ensuring the ethical and secure handling of sensitive health information in research operations. This commitment to robust security is crucial, as the MedTech industry generally faces rising cybersecurity challenges, a risk exponentially amplified when military networks and data are involved. Countries like Israel, which integrate world-leading cybersecurity expertise into their burgeoning health tech sector (over 1600 companies), demonstrate a sophisticated model for mitigating this risk. Strategic Recommendations for Investment and Policy Action For Investors and Venture Capital Funds Mandate Dual-Use Strategic Alignment and Compliance: Investment should be focused exclusively on companies that possess a defined and mature DUAL USE STRATEGY. Due diligence must confirm the maturity of Technology Transfer (T2) pathways, explicit adherence to Federal Technology Transfer Act stipulations, and robust Intellectual Property (IP) safeguards and HIPAA compliance structures. The XAI Investment Hurdle: Demand a verifiable commitment to Explainable AI (XAI) and comprehensive ethical governance models. This preemptive measure is necessary to mitigate regulatory and reputational risk associated with the potential repurposing of AI technology for lethal applications. Prioritise Ecosystem Hubs: Focus capital deployment in geographic centers of convergence, such as San Antonio, Texas, where formalized government, academic, and industrial collaboration structures (DHA/VelocityTX, TRC4) minimize translational friction and de-risk the development pipeline. For MedTech Executives Utilise Military R&D as a Cost Center Offset: Companies should strategically pursue defence contracts not merely for revenue, but as high-value, non-dilutive R&D funding for extreme product ruggedisation and performance testing under duress. This military validation should be leveraged as the core differentiator, the reliability premium, in civilian market positioning. Build Interoperable, Solution-Oriented Ecosystems: Design devices, software, and data platforms for maximal interoperability to capture the high-growth potential of the $140 Billion Digital Health Ecosystem TAM. The goal must be to combine devices and data to transition from simply selling products to providing comprehensive clinical solutions. For Policymakers and Regulators Institutionalise T2 Regulatory Consistency: The FDA and DoD must collaborate to create consistent, formalised procedures for the transfer of regulatory clearances (such as 510(k)s and De Novo pathways) to ensure seamless and rapid commercialisation. Clarification of definitions and requirements is essential to reduce administrative barriers. Establish Adaptive AI Governance: Develop agile, internationally coordinated governance frameworks that proactively address the ethical challenges of dual-use AI. This must include establishing clear accountability mechanisms for autonomous systems and mandating robust XAI standards, particularly in clinical and decision-support applications where human life is at stake. Sustain Core Research Funding: Maintain high, consistent investment levels in foundational defence research programs (DARPA, DHP) focused on acute trauma, performance optimisation and expeditionary medicine, recognizing these investments as the primary, high-velocity engines of future civilian medical advancement. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk